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Summary 
Cancer is a systemic heterogeneous disease that can undergo several rounds 
of latency and activation. Malignant tumours evolve by increasing diversity and 
in progressive response to microenvironment signals and resistance 
development after therapeutic interventions. Thus, adaptation is required for 
cancer cell survival during tumour dissemination and metastatic outgrowth.  
An epithelial-mesenchymal transition (EMT) plays a major role in 
facilitating cell plasticity in cancer and allows cancer cells to escape 
chemotherapy and targeted therapies by dedifferentiation and signalling 
adaption processes. EMT commonly describes a process in which 
differentiated epithelial cells lose their epithelial characteristics such as cell- 
cell adhesions and apical-basal polarity and gain migratory properties. While 
an EMT is mainly responsible for primary tumour cell invasion, its reversal 
mesenchymal-epithelial plasticity (MET) has been shown to contribute to the 
metastatic outgrowth of disseminated cancer cells in distant organs. Hence, 
the therapeutic reversion of an EMT in cancer could be counterproductive. 
However, it has also been noted that cells undergoing an EMT and/or an MET 
are in a state of high cell plasticity and thus, may offer a window of opportunity 
for therapeutic targeting. 
Here, I have aimed at utilizing breast cancer cell plasticity by inducing 
terminal differentiation into postmitotic adipocytes. Giving the inherent growth 
arrest of adipocytes they are unlikely to adapt and dedifferentiate, and 
therefore lose cellular plasticity. I report the efficient conversion of breast 
cancer cells, which have undergone an EMT, into functional post-mitotic 
adipocytes. By combining the diabetic drug Rosiglitazone and bone 
morphogenetic protein 2 (BMP2) I have been able to achieve almost 100% 
adipogenesis efficiency in mesenchymal breast cancer cells in vitro.  
Delineation of the molecular pathways underlying such trans-differentiation has 
motivated a combination therapy with a MEK inhibitor and Rosiglitazone to 
demonstrate the conversion of invasive cancer cells into adipocytes and the 
repression of primary tumour invasion and metastasis formation in mouse 
4 
models of breast cancer. The results indicate the high potential of utilizing the 
increased cell plasticity inherent to invasive cancer cells for differentiation 
therapy. They consequently raise the possibility of employing pharmacological 
treatments to interfere with tumour invasion and metastasis. 
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1 Introduction 
1.1 Plasticity as a General Survival Mechanism 
Plasticity refers to the adaptability of a system and its capacity to undergo 
changes. Applying this rough definition to any aspect of the world around us 
stresses the true essence of plasticity. Because when do we adapt? The 
answer is quite simple: when we are forced to. A solid piece of metal will bend 
if heated or enforced to by any other outside energy. Even an elastic rubber 
band will change its shape, only when stretched by external force. This means 
that plasticity is relevant or acknowledgeable only in the context of a stressful 
moment. The degree of plasticity of a system is known only when plasticity is 
about to be lost. When we stretch the rubber band too much it will stay in the 
stretched form or be torn – thus losing its plasticity. If the plasticity of an 
organism has reached its limit and cannot adapt to a new condition, the 
organism will die. Plasticity in biology should hence be viewed as the capacity 
to adapt and survive under changes.  
Plasticity in biology is used in various research fields such as neural 
plasticity and synaptic plasticity, cancer plasticity, plasticity in cell 
reprogramming, but also phenotypic plasticity and developmental plasticity. 
Indeed plasticity appears to be a term which explains many phenomena in 
biology.  It is required for the survival of a tissue under inflammatory stress, as 
well as the adaption of a flower to the change of season and of a population 
undergoing global warming.  
 
In this first chapter I would like to present a “zoom-in” picture of plasticity in 
order to stress its common and essential nature. I will start from a general 
overview, proceed to describe some general mechanisms in biology and 
reach eventually the kind of cell plasticity my research is concentrated on.  
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1.1.1 Evolution –Plasticity in Species  
Evolution is the natural selection over generations, whereas adaptation is the 
movement towards a phenotype that better fits the current environment (Orr, 
2005). Thus, adaptation is often reversible unless an environmental change 
endures or risks the population’s survival, in which case natural selection may 
occur (Dobzhansky, 1956).  
Referring to evolution as the plasticity of species, involves the survival 
capacity of the population in novel environments (Hollander et al., 2015) and 
its inherent (Corbett-Detig et al., 2013) or emerging epistasis (Orr, 1996).  
To understand epistasis contribution to plasticity one should first refer to the 
Darwin paradox, here explained by A. Orr (Orr, 1996): 
How could something as patently maladaptive as the evolution of 
sterility or inviability be allowed by natural selection? ... 
To see DARWIN paradox, consider the simplest possible scenario: a 
single gene causes hybrid sterility. One species has genotype AA and 
the other aa. While each species is fertile, Aa hybrids are sterile. Now 
consider how these species could evolve from a common ancestor, 
say, AA. They can’t. Starting with two allopatric AA populations, one 
simply remains AA while the other must become Aa. But how can it? 
The a mutation, like any mutation, has the unfortunate property of 
arising in the heterozygous state. But the resulting Aa individual is the 
sterile hybrid genotype, and the line comes crashing to an end. 
 
The solution to the paradox emerges when rethinking the problem in the 
context of two genes and the interaction between them, namely epistasis. The 
epistasis theory of incompatibility, also known as Bateson-Dobzhansky-Muller 
incompatibility, shows that emergence of a new mutation in population A may 
lead to hybrid sterilization, if this is incompatible with mutation of a gene in 
population B. This means that populations A (AA) and B (BB) are compatible, 
and can generate fertile hybrids of AB. Aa mutation is still fertile and so is 
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mutation Bb. However aB and Ab may cause hybrid sterility, and thus, lead to 
speciation (Dobzhansky, 1936). 
In short, enduring changes leading to favourable mutations may 
produce incompatibilities that are eventually responsible for speciation. 
Speciation increases the diversity of the total population favouring population 
survival.  
 
1.1.2  Polyphenism – Organism Plasticity 
Phenotypic plasticity is the capacity of an organism to produce different 
phenotypes in response to environmental variation (Forsman, 2015; 
Ghalambor et al., 2015). Aphids (plant lice) become winged or wingless, for 
example, depending on food availability. Tomato hornworm changes its colour 
depending on environmental temperature variations. In the cooler northern 
United States, the caterpillars that emerge in the autumn are black in order to 
absorb more sunlight. However, in the south, where camouflage is more 
important than heat conservation, caterpillars are green. In contrast, tobacco 
hornworms are typically green, regardless of temperature (Pennisi, 2006). 
Suzuki and Nijhout demonstrated how species can mask the effects of 
genetic mutations until that moment when an environmental change reveals 
them (Suzuki and Nijhout, 2006). The latency amounts to an adaptive 
mechanism that helps organisms survive under changing conditions. The 
study focuses on the tobacco hornworm mutant coloured black rather than the 
normal green. This mutation reduces secretion of juvenile hormone, which 
regulates skin colouring. This mutant strain, however, generates caterpillars 
with varying degrees of green when heat-shocked—that is, briefly exposed to 
a very high temperature—at an early stage of development. The authors 
suggest that polyphenism, depends on mutations in the mechanism that 
control hormone titre. This can shift the phenotypic threshold and reveal 
previously covert genetic variation. Subsequent small-scale changes in 
hormone titre, or in the timing of hormone secretion, can progressively reveal 
further genetic variation leading to selection.  
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The role that external stimuli variations can have on the plasticity of a 
cell population will be further discussed throughout this introduction. 
 
1.1.3  Epithelial-Mesenchymal Transition (EMT) – Cellular 
Plasticity 
In the context of species or organisms, a reciprocal connection exists between 
diversity and plasticity (Forsman, 2015). What however is plasticity in a single 
cell? A cell would markedly respond to an external signal in one way or 
another, but when can we ascribe its response to plasticity and distinguish it 
from its general cellular functioning? A possible definition is that plasticity in a 
cell equals its escape mechanism, when the cell changes to adapt itself to 
fluctuating conditions. This capacity of a cell to adapt is determined by cellular 
plasticity; therefore plasticity can be viewed as a quality of the cell. Escape 
requires the involvement of all cellular components: of cytoskeleton 
rearrangements, transcriptional and post-transcriptional changes, and even of 
altered cellular function. Such global changes take place under differentiation, 
differentiation being one domain in which plasticity is demonstrated. A stem 
cell can always differentiate, which means that it always has a powerful 
escape mechanism at hand. Stem cells and differentiation will be further 
discussed in the next chapter.  
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Another example of cellular plasticity is EMT. EMT is a process in 
which differentiated epithelial cells lose their epithelial characteristics such as 
cell-cell adhesions and apical-basal polarity and gain migratory properties 
(Box1) (Tiwari et al., 2012). 
The process of EMT is considered reversible. It is not a process of 
trans-differentiation of epithelial into a mesenchymal cell or a fibroblast; unlike 
trans-differentiation, EMT is considered a process of dedifferentiation (Berx et 
al., 2007). The full process of EMT is complex and prolonged in time. At any 
point during the process, if the signal is removed, the cells will revert to the 
Box 1 – Hallmarks of EMT:  EMT can be induced by various extracellular 
stimuli such as cytokines belonging to transformation growth factor β	(TGFβ)	
family, hypoxic conditions or matrix stiffness. These activate signalling 
cascades that regulate structural and functional changes in epithelial cells. 
(Lamouille et al., 2014; Nieto, 2013) 
Epithelial cells are constituted of sheets of cells that are tightly packed via 
specialized cell-cell junctions. One of which are the cell-cell adhesion 
junctions that require epithelial cadherin (E-cadherin). Upon EMT cells 
undergo a “Cadherin-switch”, whereby E-cadherin is downregulated and 
replaced by neural-cadherin (N-cadherin) (Christofori, 2006).  This switch is 
directly linked to the loss of cell-cell adhesions, activation of EMT regulatory 
pathways (e.g. Wnt signalling) and rearrangement of the cytoskeleton. The 
cortical actin is typical to epithelial cells and is reorganized to form stress 
fibres. The epithelial apical-basal polarity is essential to their function, and is 
lost during EMT, resulting in front-rear polarity and fibroblast-like 
morphology (Yilmaz and Christofori, 2009). 
These major morphological changes are the result but also the cause of 
transcription factor activation and EMT-associated signalling regulation. 
Transcription factors regulating EMT, such as Zeb, Snail and Twist, are 
tightly controlled at the post-transcriptional level by various micro-RNAs  
(miRNAs) (Lamouille et al., 2014). 
Members of the miR-200 family are associated with epithelial cell 
morphology and their expression is decreased upon the induction of an 
EMT.  Zeb1 and Zeb2 directly bind to miR-200 promoters and repress their 
expression, in turn miR-200 repress Zeb1/2. A number of such double-
negative feedback loops between miRNAs and key EMT TFs have been 
described. These negative feedback loops function as molecular switches 
and are important mechanisms underpinning the fine-tuning and reversibility 
of an EMT and, thus, epithelial/mesenchymal cell plasticity (Brabletz, 2012b; 
Diepenbruck and Christofori, 2016). 
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epithelial state through a mesenchymal-to-epithelial-transition (MET) 
(Lamouille et al., 2014). However, the plasticity acquired during this process 
seems to be reduced again if the signal remains in force, bringing about a 
stabilization of mesenchymal state (Zhang et al., 2014). When stabilized in the 
mesenchymal state it is hard to distinguish between EMT-derived cells and a 
fibroblast. Yet, a fibroblast is less likely to undergo MET or any other 
transition. Partial EMT refers to the different states from EMT induction to full 
mesenchymal state and can include markers of both epithelial and 
mesenchymal cells at varying levels (Nieto, 2013). These cells are in an 
unstable state and will quickly revert to the epithelial state once the external 
stimulus is removed (Figure 1). 
 
 
Figure 1: Representation of structural and cellular changes during EMT/MET  
Epithelial cells (blue) exhibit apical-basal polarity and cortical actin organization. 
Epithelium comprises tightly packed and functionally synchronized epithelial cells 
connected to each other via cell-cell junctions and are anchored to the basement 
membrane via integrins. Upon EMT, cells lose epithelial characteristics and become 
dedifferentiated single cells (partial EMT – green). The full conversion gives rise to 
mesenchymal-like cells (purple) with front-rear polarity and actin stress fibres 
formation.  
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While the removal of stimulus induces MET, it is not yet known whether 
MET-derived cells are identical to their epithelial ancestors. In embryogenesis, 
EMT and MET are of central importance as they evidently generate cells 
different from their cell of origin and are therefore crucial for normal 
development (Nieto, 2013) (See chapter: EMT and MET in Development). 
EMT and MET play a role also in wound healing processes and are 
activated in pathological contexts of organ fibrosis and cancer (Nieto, 2013). It 
is possible that in vivo partial EMT is a much more frequent event than a full 
transition (Berx et al., 2007). However, due to the unstable state of partial 
EMT and its dynamic nature, studying these events has been technically 
challenging. Lineage tracing studies concentrating on the different aspects of 
this transition can contribute to our understanding of partial EMT’s frequency 
and effects (Beck and Blanpain, 2013).  
EMT is further described and discussed throughout this work but I 
would like to give one example at this point that emphasizes the plasticity 
cells gain during an EMT. EMT is in fact an embryological, tightly regulated 
process. From the early stages of gastrulation and throughout organogenesis, 
EMT and MET facilitate embryonic development (Nieto, 2013) (See chapter: 
EMT and MET in Development).  The reversibility of these processes hints 
that certain plasticity endures in cells undergoing EMT or MET (Berx et al., 
2007). These processes can be reactivated in pathological conditions such as 
chronic inflammation and cancer. This correlation between developmental 
EMT and pathological EMT can be well demonstrated in the case of kidney 
fibrosis: 
The generation of the kidney epithelium is the result of several rounds of EMT 
and MET. The entire epithelium of the kidney is derived from the intermediate 
mesoderm during the urogenital development. The mesodermal cells undergo 
a mesenchymal-epithelial transition to form the kidney’s epithelium (Kalluri 
and Weinberg, 2009). Snai1 is an important transcription factor regulating 
EMT by repressing E-cadherin expression or cadherin-16 in the case of 
kidney epithelium (Grande et al., 2015). Snai1 is expressed in the precursors 
of the renal epithelial cells and is downregulated upon epithelial differentiation. 
Thus, Snai1 is maintained in a silent state during adulthood. The reactivation 
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of Snai1 in renal epithelial cells leads to renal fibrosis and renal failure in an 
inducible transgenic mouse model (Boutet et al., 2006). Snai1 expression is 
induced in chronic inflammation by a persisting inflammatory stress mediated 
by cytokines, such as TGFβ. EMT in organ fibrosis is a complex process that 
might have its origin in kidney development. By retaining some imprint of their 
mesenchymal origins, kidney epithelial cells may be particularly prone to 
undergo EMT. In agreement with the concept of high plasticity in kidney 
epithelium, it has been observed that EMT in kidney fibrosis is highly 
heterogeneous; the cells undergo EMT to a different extent omitting an 
invasive phenotype. Therefore, EMT in kidney fibrosis is considered partial 
EMT. (Grande et al., 2015; Nieto et al., 2016) 
The dynamic nature of EMT and MET leads to increased plasticity. The 
end points of these transitions, namely full epithelial or full mesenchymal 
states, are usually relatively stable (Greenburg and Hay, 1982; Nieto et al., 
2016).  Nevertheless, one can legitimately hypothesize that every epithelial 
cell carries a corresponding ability to undergo EMT. 
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1.2 Stem Cells and Plasticity 
1.2.1 Stem Cells  
Stem cells are classically defined by their ability to self-renew and to 
differentiate. Long-term self-renewal is characterized by the ability to produce 
at least one identical daughter cell. The ability to differentiate refers to the 
potential of the cell to give rise to more than one type of differentiated cell. If a 
cell can differentiate only within one specific lineage, it is considered a 
progenitor and not a stem cell. Totipotent stem cells can differentiate into all 
cell types including extraembryonic tissues (placenta, yolk sac and supporting 
tissues). Pluripotent stem cells can generate all cell types of the organism, 
and multipotent stem cells produce cells of a specific tissue. Unipotent stem 
cells, such as spermatogonial stem cells, share the capacity for self-renewal, 
yet exhibit limited developmental potential giving rise to only a single cell type, 
such as sperm. (Laplane, 2016)  
Most adult stem cells, however, are considered multipotent stem cells. 
They are residents of a specific tissue, responsible for the tissue’s 
homeostatic self-renewal and can be rapidly recruited in case the need of 
regeneration arises (Reya and Clevers, 2005). Adult stem cells are 
maintained in specialized niches in a quiescent state. The stem cell niche, or 
in other words the stem cell microenvironment has crucial role in maintaining 
the stem cells in their multipotent state. This is not a trivial quest, since 
maintaining the stem cell potential means stem cells are kept away from 
signals that will induce their differentiation. Differentiation can be induced not 
only through differentiation signals but it also requires the cells entering into 
cell cycle. Indeed, keeping the cells in a quiescent state is one of the major 
roles of the niche to avoid stem cells exhaustion (Cheng et al., 2000; Orford 
and Scadden, 2008; Porlan et al., 2013).  
One can argue that a stable stem cell state is a challenge confronted 
only by adult stem cells. In fact, the pluripotent stem cells of the developing 
embryo keep their state only transiently. It is already during the transition from 
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8- to 16-cell stage in early mammalian development that different cell lineages 
arise for the first time. A recent study demonstrates that differences in 
contractility and polarity confer different fates in the 16-cell stage (Maitre et 
al., 2016). The daughter cells congregating at this stage have differential 
levels of contractility due to asymmetric segregation of a polarized apical 
domain at cell division. In the less-contractile polar cells, the transcriptional 
activator protein YAP enters the nucleus and activates a gene-expression 
program giving rise to the trophecdoterm. The highly contractile cells at this 
early stage do not have nuclear YAP, and localize to the centre of the cell 
aggregate to eventually become the inner cell mass, from which the embryo 
will form (Maitre et al., 2016).   
The broadly studied embryonic stem cells (ESC) are in fact pluripotent 
stem cells expanded in vitro from the inner cell mass of the embryo 
(Weinberger et al., 2016). They are pluripotent because they can give rise to 
cells from the three germ layers in vitro and in vivo. During gastrulation they 
rapidly proliferate and differentiate. Maintaining self-renewal in vivo or ex vivo 
requires transformation, explaining why ESC give rise to tumours called 
teratomas or teratocarcinomas upon re-transplantation or reactivation (Burdon 
et al., 1999). Another interesting point is that teratomas are highly 
differentiated tumours. The cells that composite the teratomas are cells of the 
three germ layers but are usually of terminal differentiated phenotype (hair 
and teeth- like structures are frequently found in these tumours) (Pierce and 
Dixon, 1959). Indeed these tumours are usually considered benign. When 
ESC are expanded in vitro they are maintained in a special medium 
containing leukaemia inhibitory factor (LIF), which activates the JAK–STAT3 
(Janus kinase–signal transducer and activator of transcription 3) pathway. LIF 
is a key ingredient that supports ESC propagation in the undifferentiated state 
(Weinberger et al., 2016). Once LIF is removed, the cells rapidly commit to a 
specific lineage. When these cells are re-transplanted or re-activated in vivo 
they undergo differentiation in the form of a teratoma (Weinberger et al., 
2016).  
These features of embryonic stem cells suggest the necessity of stem 
cell niches in adult tissue. Stem cell function in the niche is tightly regulated by 
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morphogens (including Notch, Wnt and Hedgehog), cell–cell and cell–
extracellular matrix (ECM) adhesion molecules (cadherins and integrins) as 
well as hypoxic conditions (Laplane, 2016). Self-renewal requires the exact 
positioning of the mitotic spindle to allow the generation of two different 
daughter cells (Clevers, 2005; Maitre et al., 2016). Thus, any change in the 
microenvironment may lead to differentiation. 
Plasticity seems inherent to the understanding of stem cell function. 
Stem cells are considered plastic cells, since they can easily change their 
phenotype. They are so prone to change and adaptation that every slight 
change will lead to their differentiation.  
 
1.2.2 EMT and MET in Development 
EMT plays an essential role in implantation, embryogenesis and organ 
development. Both embryo implantation and the initiation of the placenta are 
associated with EMT involving the parietal endoderm. The trophectoderm 
cells undergo an EMT in order to facilitate invasion into the endometrium and 
the following anchoring of the placenta (Kalluri and Weinberg, 2009). During 
gastrulation the primitive epithelium (epiblast cells) migrate toward the centre 
of the embryo to form the mesoderm. This ingression of mesendodermal 
precursors at the primitive streak requires EMT both for the cell migration and 
for the generation of primary mesoderm. A MET that follows generates the 
endodermal layer. EMT also enables delamination of the neural crest (Nieto, 
2013). 
Mesodermal cells then migrate to occupy different positions along the 
medio-lateral axis of the embryo. Upon MET these cells generate notochord, 
somites and the urogenital system. Organogenesis then often requires further 
rounds of EMT and MET (Locascio and Nieto, 2001; Nieto, 2013).  
It is intriguing that EMT and MET in early development involve different 
types of stem cells. In fact, EMT directly induces primitive epithelium stem 
cells to become pluripotent, by allowing their differentiation into cells of both 
the endodermal and mesodermal layer. As mentioned above, at least some 
epithelial cells, though differentiated, maintain the ability to undergo EMT. 
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This possibly suggests that cellular plasticity is a quality contemporaneous 
with the differentiation state of a cell and not a property enhanced by 
stemness (Figure 2). Of course not all cells can easily change their 
phenotype. As discussed earlier, plasticity potentially increases the survival of 
a population. Perhaps it is due to the high plasticity potential of epithelial cells 
(Donati and Watt, 2015) that they are more prone to undergo malignant 
transformation. This hypothesis is further supported by the observation that 
skin keratinocytes, an epithelial cell type, give rise to induced pluripotent stem 
cells (iPSCs) more efficiently and faster than fibroblasts (Aasen et al., 2008; 
Maherali et al., 2008). 
 
 
  
1.2.3 Induced Pluripotent Stem Cells (iPSC) 
Overexpression of the transcription factors Oct4 (Pou5f1), Klf4, Sox2, and c-
Myc (OKSM) in somatic cells gives rise to induced pluripotent stem cells 
(iPSCs) in a process named cell reprogramming. IPSC exhibit molecular and 
functional similarities to ESC (Takahashi and Yamanaka, 2006). The 
generation of a pluripotent stem cell from a somatic- embryonic or adult cell is 
Figure 2: EMT enhances cellular plasticity regardless of differentiation state 
A stem cell can undergo differentiation to a specific cell type. However, both the 
differentiated cell as well as the stem cell can undergo EMT-like processes that will 
increase cell plasticity. Suggesting that cell plasticity is contemporaneous with cell 
differentiation state. 
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a powerful tool for studying numerous degenerative diseases with a clear 
therapeutic potential.  
Reprogramming is considered efficient when at least the following 
functional assays deliver results comparable with those of ESCs. 1. In vitro 
differentiation to derivatives of all three embryonic germ layers—ectoderm, 
mesoderm and endoderm. 2. The teratoma formation assay assesses the 
spontaneous generation of differentiated tissues from the three germ layers 
following the injection of cells into immune-compromised mice. 3. The 
blastocyst chimaera formation determines whether test cells can re-enter 
development when introduced into host embryos at either of two pre-
implantation stages: by aggregation with cleavage-stage morulas or by 
injection into blastocysts. Pluripotent stem cells should support normal 
development and generate high-grade chimaeras with extensive colonization 
of all embryonic tissues including the germ line (De Los Angeles et al., 2015). 
These assays test the pluripotency of stem cells generated and expanded in 
vitro. The initial identification of iPSC following the conversion is usually done 
on hand of Nanog expression (Stadtfeld et al., 2008). Reprogramming has 
also proven possible in vivo, whereby a transitory induction of OSKM factors 
in mice generated teratomas originating from various epithelial structures 
(Abad et al., 2013). 
Reprogramming is usually slow and inefficient (1-3%) (Apostolou and 
Hochedlinger, 2013). Various approaches emerged over the few years since 
this popular field opened its gates to overcome the parsimonious efficiency of 
this process. In 2013, small interfering RNA (siRNA) screen of epigenetic 
factors, revealed Mbd3, a component of the nucleosome remodelling and 
histone deacetylase (NuRD) complex, as a clear repressor of reprogramming. 
By downregulating Mbd3 together with OSKM transduction nearly 100% of 
mouse embryonic fibroblasts (MEF) were reprogrammed into iPSC within 6-8 
days. The authors suggested that Mbd3 is recruited once the factors are 
introduced and represses their function. Similar efficiency was achieved in 
different cell lines, including in terminally differentiated cells such as mature B- 
and T-cells. Mbd3 was shown to inhibit reprograming until the late stages of 
the process. Nevertheless, once reprograming was achieved, Mbd3 
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expression had no effect on the maintenance of pluripotency (Lujan et al., 
2015; Rais et al., 2013). 
By transiently overexpressing CCAAT/enhancer binding protein-α 
(C/EBPα) prior to the introduction of the OSKM factors B-cells were efficiently 
(~95%) reprogrammed within 12 days.  Importantly, the enhanced efficiency 
was achieved only when using B-cell precursors and not by using terminally 
differentiated mature B-cells or MEF. The transient expression of C/EBPα 
correlated with the gain of mesenchymal markers. The authors suggested that 
the expression of mesenchymal markers induced with C/EBPα enabled the 
activation of MET and consequently of cell reprograming. C/EBPα was shown 
to induce reprograming by activating Tet2, which enables Oct4 binding to 
pluripotency inducing genes (Di Stefano et al., 2014). 
 
1.2.4 EMT and MET in Cell Reprogramming 
Reprogramming is a process in which somatic cells gradually lose their 
differentiated identity and assume embryonic gene expression pattern and 
growth behaviour. It is a multi-stage process involving early stochastic and 
late deterministic phases. The stochastic model describes the unpredictability 
of reprogramming in a cell population, demonstrating that reprogramming 
depends on the number of cell divisions. A sequence of probabilistic 
events eventually lead to the small and unpredictable fraction of iPSC (Hanna 
et al., 2009). The deterministic late phase refers to hierarchical gene 
activation circuitry towards pluripotency after the initial gene expression 
changes (Buganim et al., 2012). 
The inefficient and stochastic nature of reprogramming left the 
mechanisms governing reprogramming largely obscure in the first years. 
However, the emergence of single cell technologies on one hand and 
achieving 95-100% efficient reprogramming on the other hand enabled the 
deciphering of this process to some extent. This conversion is accompanied 
by drastic morphological changes generating multilayered epithelial-like cells. 
However, the different approaches and juvenility of the field lead to a quite 
confusing picture of the mechanisms underlying reprogramming. 
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Nevertheless, some interesting insights regarding the process have been 
described and demonstrated. 
Two major waves of gene expression changes are typical for the early 
extinction of somatic genes and the late activation of core pluripotency genes 
(Apostolou and Hochedlinger, 2013; Buganim et al., 2012). The intermediate 
phase of reprogramming is poor in major transcriptional changes, suggesting 
that cells undergo gradual epigenetic alterations to prime the genome for 
transcriptional activation of pluripotency genes. In agreement with this is the 
observation that histone marks associated with pluripotency enhancers are 
established at early and intermediate stages of reprogramming. The 
establishment of pluripotency-specific long-range chromatin interactions and 
Tet-mediated conversion of 5mC into 5hmC at pluripotency promoters also 
characterize the intermediate period. DNA methylation is considered to be the 
most stable epigenetic modification occurs late in the process (Apostolou and 
Hochedlinger, 2013). 
This suggests that plasticity of reprogrammed cells is enhanced in the 
early and intermediate phases of reprogramming, whereas the late phase 
requires the stabilization of the cells in a stem cell state. In agreement with 
this data, EMT and MET like processes seem to facilitate cell reprogramming 
mostly in the early and intermediate phases. Although reprogramming is 
frequently induced in fibroblasts or B-cells, it has been shown that EMT- 
related transcription factors are suppressed to allow MET activation (Di 
Stefano et al., 2014; Liu et al., 2013; Samavarchi-Tehrani et al., 2010). The 
data demonstrate that the induction of reprogramming includes the 
suppression of epithelial genes as well as the upregulation of mesenchymal 
genes (Di Stefano et al., 2014), even in the conversion of fibroblasts to iPSC 
(Liu et al., 2013). The OSKM factors can directly induce or suppress EMT 
related transcription factors, such as Snail1 (Li et al., 2010; Nieto et al., 2016). 
In turn MET is actively induced by the regulation of Klf4 (Li et al., 2010) or 
external MET inducers such as bone morphogenetic proteins (BMPs) 
(Samavarchi-Tehrani et al., 2010).  
One can rightfully argue that the MET-like changes are required merely 
for the upregulation of the epithelial protein E-cadherin (encoded by the gene 
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Cdh1) which is also expressed in ESC and iPSC. However, hints to a prior 
EMT-like process as well as the timing of these transitions during the time 
course of reprogramming from different cell types suggest that EMT and MET 
coincide with increased plasticity required for reprogramming. 
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1.3 Cancer Plasticity  
As discussed in the previous chapters, the survival of a population is achieved 
through its inherent variations (epigenetic modifications, mutations, epistasis), 
and its capacity to undergo adaptation induced by dynamic changes. On the 
cellular level, adaptation is possible via EMT and MET which enhance cell 
plasticity.  
Diversity in a tumour cell population increases its survival potential. 
External signals from the tumour microenvironment trigger cancer cell 
plasticity via processes like EMT/MET. Plasticity is exhibited in the varying 
responses of cells depending on cell state and location, thus creating a variety 
of phenotypic changes (Figure 3).  
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In this chapter I would like to emphasize the different aspects of plasticity in 
breast cancer and its contribution to disease progression (Figure 4). 
 
 
Figure 4:  Cancer plasticity and the metastatic cascade of breast cancer. The 
primary tumour site is highly heterogeneous and comprises epithelial cell 
populations with different mutations, proliferation states and differentiation 
phenotype. At the invasive tumour front, epithelial cells respond to 
microenvironment signals such as TGFβ by undergoing EMT (purple cells) to 
varying extent. Cell clusters can detach from the primary tumour exhibiting mixed 
expression of epithelial and mesenchymal genes as demonstrated in partial EMT 
(green cells). Migratory tumour cells disseminate through blood vessels and 
extravasate at distant organs. The primary tumour is surgically removed and 
systemic therapy is usually applied triggering drug resistance and dormant cancer 
cell formation. These cells are reactivated at distant site and revert to their former 
differentiated state to allow metastatic outgrowth via MET.  
Figure 3: Plasticity and diversity in a cell population 
This figure represents the inherent plasticity of every differentiated state and of every 
cell type on the vertical axis. Differentiated states are on the left where different 
colours are marked, and dedifferentiated and stem cell-like states are on the right 
where colours are light.  Cell diversity includes cell identity, mutations and epigenetic 
landscape of cells creating cellular heterogeneity. Plasticity induced by dynamic 
changes is represented on the horizontal axis. Plasticity is triggered by external 
signals from the tumour microenvironment and is exhibited in the varying response of 
cells depending on cell state and location, thus creating a variety of phenotypic 
changes. 
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1.3.1 Heterogeneity 
Tumour heterogeneity coincides with major challenges to cancer diagnosis 
and treatment success. The primary tumour site comprises cell populations 
with different mutations, proliferation states and differentiation phenotype. For 
example in breast cancer, the same tumour can combine cells extensively 
expressing oestrogen receptor (ER) and cells negative for ER. Intriguingly, 
these two populations can arise from the same cell of origin (Keller et al., 
2012). Thus the histopathological analysis of the tumour has to base on 
different sites. The treatment is usually decided according to the more 
malignant counterparts of the tumour and its receptor status (Koren and 
Bentires-Alj, 2015). 
A further aspect of heterogeneity concerns the tumour’s cell of origin. 
The mammary gland contains two types of epithelial cells. The luminal layer 
lining the ducts and alveoli is characterized by the expression of oestrogen 
and/or progesterone receptors and apical-basal polarity. The myoepithelial 
cells are typically of a basal location and function as the contractile apparatus 
of the gland with specialized cytoskeleton arrangement and the expression of 
its contractile protein smooth muscle actin (SMA) (Weigelt and Bissell, 2008). 
This basal layer has been a source of confusion due to its communalities with 
basal or triple-negative (negative for ER, progesterone receptor (PR) and 
HER2 receptors) breast cancer cells. However, studies demonstrate that the 
myoepithelial cells are usually less likely to undergo malignant transformation, 
suggesting that the highly invasive basal-like cells do not originate from the 
myoepithelial lineage (Gudjonsson et al., 2005). 
 Two recent studies support this notion by underlining the multipotency 
role of PIK3CAH1047R oncogene in breast cancer (Koren et al., 2015; Van 
Keymeulen et al., 2015). The authors demonstrate how the expression of the 
frequent breast cancer mutation PIK3CAH1047R in basal or luminal cells gives 
rise to tumours with different degrees of malignancy. The mutation induces 
mammary cell plasticity and enhances tumour heterogeneity when expressed 
in either of the cells of origin. However, heterogeneous tumours arising from 
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luminal mammary cells show gene expression similarities to more aggressive 
breast cancer subtypes and more frequent malignant lesions than tumours 
derived from basal cells, which show mostly a benign phenotype (Koren et al., 
2015). 
Analysing the genetic diversity evolution and driver mutations in 
tumours demonstrates the development and proliferation of robust clones 
(Koren and Bentires-Alj, 2015). Single cell analysis from a primary tumour and 
its liver metastasis indicated that a single clonal expansion formed the primary 
tumour and seeded the metastases (Navin et al., 2011).  
Taken together, tumour heterogeneity refers to different parameters of 
the tumour such as genetic diversity, cell type and receptor status variability 
as well as lineage plasticity, all of which contribute to the survival of the 
tumour.  
 
1.3.2 Cancer Stem Cells (CSC) 
The concept of CSC is disputable which generates diverse definitions, making 
the discourse on CSC even more complex (Clevers, 2011; Koren and 
Bentires-Alj, 2015; Pattabiraman and Weinberg, 2014). CSC are also referred 
to as cancer-initiating cells or cancer-propagating cells, whereas each term 
actually stands for a different function of these cells (Laplane, 2016). This 
moot question regarding stem cells possibly has its roots in cancer plasticity, 
but to address the question of cancer plasticity we will have to come to terms 
with the lack of clarity as described above.  
A major question in the CSC field refers to the cell-of-origin of a tumour 
(Beck and Blanpain, 2013). Is cancer a disease originating in a transformed 
stem cell (hierarchical model) (Pardal et al., 2003) or do CSC have their 
ancestors in non-stem cancer cells (Koren and Bentires-Alj, 2015)? A further 
possible variation implies that oncogene activation can directly induce 
stemness in non-stem cells (Koren et al., 2015).  Cancer types, like 
teratomas, or some types of leukaemia, like Acute promyelocytic leukemia 
(APL), seem to fit the hierarchical model (Clevers, 2011). However, tumours 
originating from epithelium (carcinomas) are able to undergo dedifferentiation 
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processes like EMT, demonstrating that CSC could originate from non-stem 
cells (Lamouille et al., 2014).  
A recently published book by Lucie Laplane, entitled “cancer stem 
cells: philosophy and therapy” represents a deconvolution of the concept of 
CSC (Laplane, 2016). Laplane demonstrates through a comprehensive 
analysis that the complexity of the field has its roots in vague definitions of 
basic terms such as stem cells and dedifferentiation. These unclarities 
originate in our incomplete understanding of the nature of stemness (Zipori, 
2004). To overcome these challenges Laplane suggests a new definition to 
the concept of stemness divided into four versions:  
1. Categorical: Stemness is an intrinsic and essential property of a stem 
cell, independent of its environment.  
2. Dispositional: Stemness is essential and specific to stem cells but the 
expression of stemness depends on extrinsic factors. Thus, stemness 
emerges only in the right environment.  
3. Relational: Stemness is an extrinsic property induced in a cell that 
would otherwise be a non-stem cell by its microenvironment.  
4. Systemic: Stemness is an extrinsic property of a system such as 
tissue, rather than an individual cell. Thus, stemness is regulated by 
factors maintaining tissue homeostasis. 
 
Taken together, cancer stem cells, although broadly studied are ill defined. 
This has to do with the evasive definition of stemness and possibly with the 
transient dynamic nature of CSC. Considering cellular plasticity as a quality 
contemporaneous to differentiation state, it is possible that targeting CSC 
alone will not inhibit cancer plasticity. 
 
1.3.3 Microenvironment, EMT and MET 
Cancer is a systemic disease that can frequently result in metastatic 
dissemination, which is the main cause of cancer-associated death. The 
formation of distant metastasis requires the invasion of primary tumour cells, 
dissemination through blood vessels, seeding at the distant site, and 
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colonization of the host organ to form macrometastases (Brabletz, 2012b) 
(Figure 4). Metastatic cells need to survive blood circulation, evade immune 
defences, and adapt to a constantly changing microenvironment: as a 
consequence, metastasis is a highly inefficient process (Diepenbruck and 
Christofori, 2016; Massague and Obenauf, 2016).  
How do tumour cells overcome microenvironmental changes? It has 
been demonstrated that a small population of cells via direct non-cell-
autonomous stimulation can support tumour growth. A sub-population of cells 
in the tumour can stimulate proliferation of all tumour cells by inducing 
tumour-promoting microenvironmental changes. Hence, intra-tumoural sub-
clonal interactions can facilitate metastatic outgrowth (Marusyk et al., 2014).  
Tumour cell dissemination is an early event in cancer progression also 
in cancer types that are considered curable (Husemann et al., 2008). 
Clinically, cancer relapses within months or decades after initial tumour 
removal and treatment in the form of a metastatic disease is a frequent 
outcome. This latency between primary cell dissemination and metastatic 
outgrowth remains largely elusive due to technical challenges in studying 
molecular mechanisms over a long period of time (Massague and Obenauf, 
2016). Yet, clinical studies investigating blood circulating tumour cells (CTC) 
and tumour cells in bone marrow of early stage cancer patients provided first 
insights into the molecular state of these cells, demonstrating their quiescent 
state (dormancy) (Pantel et al., 2008). Moreover, the incidence of 
disseminated tumour cells in the bone marrow is a predictor of metastatic 
disease with a higher prognostic value than CTC (Massague and Obenauf, 
2016; Pantel et al., 2008). Nevertheless, given the necessary step of 
disseminating tumour cells to intravasate and survive in the circulation, 
studies focusing on CTC are of highly clinical relevance. Notably, CTC can be 
detected both as single cells and as CTC clusters. The latter exhibit gene 
expression of both epithelial and mesenchymal genes (partial EMT) and 
demonstrate a higher probability to survive the circulation and to form 
metastasis (Aceto et al., 2014; Diepenbruck and Christofori, 2016). 
Micrometastasis in other organs than bone marrow also shows features of 
dormancy induced by immune response and microenvironmental signals. 
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These together with an insufficient vascularization at the distant metastatic 
site create a stem cell-like niche that supresses proliferation (Gao et al., 
2012b; Massague and Obenauf, 2016).  
Various in vivo models were able to shed light on the mechanisms 
underlying tumour cell dormancy and survival. Disseminating cancer cells 
reside in specialized niches resembling adult stem cell niches (Massague and 
Obenauf, 2016). Existing stem-cell niches are rich in extracellular signalling 
molecules, such as members of the TGFβ family, Hedgehog, Wnt and the 
chemokine CXCL12 (Gao et al., 2012b; Massague and Obenauf, 2016; Zhang 
et al., 2013). These signals supress re-differentiation and keep cells in a 
quiescent state, which in turn leads to therapy resistance (Brabletz, 2012b; 
Giancotti, 2013).  
EMT and MET are induced by external stimulation as the result of a 
tumour cell’s interaction with the microenvironment at different sites and 
stages in tumour progression.  A lineage-tracing model to study the effect of 
TGFβ-responsive cells in squamous cell carcinoma revealed its role in 
malignant progression. The authors demonstrate the direct effect of TGFβ on 
tumour cells localized in the perivascular niche as an underlying mechanism 
for non-genetic tumour heterogeneity. TGFβ-responsive cells show reduced 
proliferation, aberrant differentiation along with EMT changes and an invasive 
phenotype with enhanced drug resistance. The data indicates that TGFβ in 
the tumour microenvironment generates dedifferentiated resistant cells that 
eventually lead to tumour recurrence (Oshimori et al., 2015). 
Further evidence for a TGFβ response was found in tumour cells’ 
passage in the circulation. Intravascular tumour-platelet interaction promoted 
metastasis via platelet-derived TGFβ. TGFβ and platelet elements directly 
induced EMT and the upregulated expresssion of prometastatic genes in 
tumour cells (Labelle et al., 2011). 
Another environmental contribution to metastasis formation is the 
recruitment of non-tumour cells to the metastatic site to facilitate metastatic 
outgrowth. It has been demonstrated in mouse models of breast cancer that a 
bone marrow-specific population of myeloid progenitor cells recruit almost 
exclusively to the metastatic lung. The recruited myeloid cells showed 
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increased expression of Versican in the lung with direct correlation to 
metastatic outgrowth. Further analysis revealed that Versican expressed by 
myeloid cells directly induced MET in metastatic cells, enabling metastasis 
outgrowth (Gao et al., 2012a). 
Further data support the notion that upon metastatic colonization 
cancer cells need to undergo MET in order to overcome the EMT-induced 
growth arrest (Ocana et al., 2012; Tsai et al., 2012). However, highly 
aggressive carcinomas, such as triple negative breast cancer sub-types, often 
maintain a claudin-low and inherent EMT-like phenotype at the metastatic 
sites. This phenotype is also observed in short- term relapsed patients with an 
originally differentiated sub-type. This type of metastatic disease is puzzling in 
view of our current understanding of tumour dormancy and metastatic 
colonization, suggesting two distinct metastasis pathways (Brabletz, 2012b; 
Diepenbruck and Christofori, 2016).   
Yet, some studies focusing on mesenchymal, basal-like breast cancer 
models contribute to our understanding of the possible mechanisms 
responsible for cancer progression in these aggressive tumours. Single cell 
analysis of a metastatic signature in triple-negative (ER−/PR−/HER2−), basal-
like patient-derived xenograft (PDX) models was preformed using a 
microfluidics-based platform (Fluidigm). This technique allowed a multiplex 
gene expression analysis in individual cells. Early-stage metastatic cells (low 
burden) expressed a distinct basal/stem-cell signature with upregulation of 
pluripotency genes as well as EMT markers (Lawson et al., 2015). 
Furthermore, the mesenchymal invasive human cell line MDA-MB-231 
showed an increase in EMT markers upon chemotherapeutic drug treatment. 
EMT was directly responsible for the drug resistance in these cells (Saxena et 
al., 2011). 
These results raise the possibility that in the context of dedifferentiated 
invasive cancer cells, a cancer cell can still be induced to undergo EMT or 
MET that will allow further adaptation. The consequence of this transition is 
not a full phenotypic change, but rather an enhancement of plasticity. This 
hypothesis is in agreement with the concept of plasticity as discussed in the 
previous chapters: 
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• Cellular plasticity is a quality contemporaneous to the differentiation 
state of a cell and not a property enhanced by stemness (Figure 2). 
• EMT and MET-like changes are required for cellular reprogramming 
regardless of the cell type. Also MEF and B-cells can undergo initial 
EMT inducing their conversion into iPSC, suggesting that EMT and 
MET coincide with increased plasticity required for cellular 
reprogramming (See Chapter: EMT and MET in Cell Reprogramming). 
 
1.3.4 Therapy Resistance 
Breast cancer therapy typically starts with the surgical removal of the primary 
tumour. In some cases of more advanced disease neoadjuvant therapy to 
shrink the tumour is given prior to surgery. Treatment decisions are not trivial 
in breast cancer therapy and are the result of interdisciplinary discussion 
between surgeons, oncologists and pathologists. Generally, hormone-positive 
cancer types (ER+/PR+) will be treated with specific inhibitors, whereas triple-
negative or highly proliferative, aggressive subtypes will be treated with 
chemotherapy. Tumour resistance to chemotherapy and targeted therapies is 
one of the main reasons for cancer recurrence and mortality.  
Drug resistance can be intrinsic (present before treatment) or acquired 
during treatment by various therapy-induced adaptive responses. Indeed 
cancer therapy resistance is a paradigm of cancer plasticity; diverse 
molecular mechanisms have been implicated in tumour cell adaption to 
therapy (Holohan et al., 2013). These include increased rates of drug efflux 
mediated by ABC-transmembrane protein family members, activation of 
survival signalling pathways and the inactivation of apoptosis signalling 
pathways can also lead to drug resistance. Tumour heterogeneity, epigenetic 
changes, microenvironment influence and CSC have also been identified as 
important contributors to chemoresistance. Dormant cancer cells are 
intrinsically resistant to many therapeutic approaches, which typically target 
dividing cells. As mentioned above many of these mechanisms leading to 
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resistance have been directly linked to tumour-dedifferentiation and EMT 
(Holohan et al., 2013; Ma et al., 2015). 
A further interesting example comes from HER2 expression patterns in 
resistant tumours. HER2+ breast cancer cells exhibit aggressive phenotype, 
with loss of epithelial characteristics and invasiveness (Moasser, 2007). The 
development of anti-HER2 targeted therapy (Trastuzumab) has significantly 
improved the survival of HER2+ breast cancer patients. However drug 
resistance is a common event in this type of tumours, and correlates with 
PTEN loss. Resistant cells often lose HER2 expression and express EMT-
related markers (Burnett et al., 2015).  This suggests that EMT program 
correlates with malignancy regardless of cell phenotype. 
A recent study investigated the observed clinical transition in HER2 
expression patterns after chemotherapy (Jordan et al., 2016). After multiple 
courses of therapy, women with advanced ER+/HER2- breast cancer acquire 
a HER2-positive subpopulation of CTC. HER2+ CTC counterparts are more 
proliferative but not addicted to HER2 due to the activation of multiple 
signalling pathways. However the HER2− subpopulation of circulating tumour 
cells show activation of Notch and DNA damage pathways, exhibiting 
resistance to cytotoxic chemotherapy, but sensitivity to Notch inhibition. This 
is in agreement with the drug resistance premise, since these tumours 
originate from well-differentiated ER+ breast cancer cells, but they activate 
cancer stem cell-associated pathways, such as Notch signalling, to survive 
treatment. The authors demonstrate that the HER2+ subpopulation 
spontaneously arises from therapy-resistant HER2- cells. The more rapidly 
proliferating single HER2+ CTCs also generated HER2− progeny. Single cell 
RNA sequencing revealed the activation of a MET program in the newly 
generated HER2+ cells.  
Taken together, the data demonstrate the high plasticity acquired by 
chemotherapy-resistant cancer cells allows a rapid inter-conversion between 
phenotypes, which involves EMT and MET-like processes.   
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1.4 Plasticity as a Challenge in Cancer Therapy 
Cancer cell plasticity plays a critical role in cancer survival, invasion and 
metastasis formation (Massague and Obenauf, 2016), as well as in tumour 
heterogeneity (Koren et al., 2015; Van Keymeulen et al., 2015) and in the 
development of therapy resistance (Gupta et al., 2009; Jordan et al., 2016). 
Cancer cell plasticity is of a dynamic nature and can be the result of changing 
cues in the microenvironment (Oshimori et al., 2015). An epithelial-
mesenchymal transition (EMT) seems to play a major role in facilitating cell 
plasticity in cancer and allows cancer cells to escape chemotherapy and 
targeted therapies by dedifferentiation and signalling adaption processes 
(Gao et al., 2012b; Labelle et al., 2011; Nieto, 2013; Valiente et al., 2014). 
Targeting EMT-derived cells by specific cytotoxic compounds, such as 
Salinomycin (Gupta et al., 2009), or by inducing their re-differentiation via 
MET (Pattabiraman et al., 2016) has been proposed as a possibility to 
overcome metastasis.  
While an EMT is mainly responsible for primary tumour cell invasion, its 
reversal MET, has been shown to contribute to the metastatic outgrowth of 
disseminated cancer cells in distant organs (Ocana et al., 2012; Tsai et al., 
2012). Hence, the therapeutic reversion of an EMT in cancer could be 
counterproductive (Nieto, 2013). However, it has also been noted that cells 
undergoing an EMT and/or an MET are in a state of high cell plasticity and 
thus may offer a window of opportunity for therapeutic targeting (Brabletz, 
2012b; Laplane, 2016; Nieto, 2013; Nieto et al., 2016).  
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1.5 Differentiation Therapies 
1.5.1 Differentiation Therapy in Solid Tumours by G.B. Pierce 
The notion that cancer stem cells can be induced to undergo differentiation 
has been suggested by G.B. Pierce in his study of teratomas in 1959 (Pierce 
and Dixon, 1959). This initial study was followed by a life-time work of Pierce 
on the concept of cancer stem cells and differentiation potential, establishing 
a crucial milestone in the field of stem cell biology (Pierce, 1993). Supported 
by his revolutionary studies on CSC and hierarchical tumour development 
Pierce was resistant to the concept of tumour dedifferentiation (Pierce, 1993; 
Pierce et al., 1977). His results rather demonstrate as he describes "cancer 
cells as a caricature of the normal process of tissue renewal" (Pierce, 1993). 
This notion implies that all tumours originate from tissue stem cells and that 
tumours differ only in the potential for differentiation of their stem cells: 
embryonal carcinomas form the three germ layers, breast cancer stem cells 
form only glandular epithelium, and stem cells of squamous cell carcinoma of 
the skin differentiate into well-differentiated squamous cells (Pierce and 
Dixon, 1959; Pierce et al., 1977; Pierce and Wallace, 1971). Indeed in this 
latter report, Wallace and Pierce demonstrate that the progeny of malignant 
stem cells can differentiate into benign cells incapable of forming a tumour 
(Pierce and Wallace, 1971). 
 
1.5.2 Differentiation Therapy in Leukaemia  
APL is a distinct highly malignant subtype of acute myeloid leukaemia. It is 
characterized by a chromosomal translocation, which results in the fusion 
between the promyelocytic leukaemia (PML) gene and the retinoic acid 
receptor (RAR) gene. Early treatment with chemotherapy was the front-line 
treatment of APL with limited remission success and low long- term survival 
rate (Wang and Chen, 2008). 
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A new era in the treatment of this disease began with a differentiation 
therapy approach initially developed in China. As the authors describe, this 
new direction in cancer treatment has its origins in disease control models 
employed in China that had been influenced by the Chinese ancient 
philosophy on the management of society. These are best illustrated by 
Confucius’ famous saying: “If you use laws to direct the people, and 
punishments to control them, they will merely try to evade the laws, and will 
have no sense of shame. But if by virtue you guide them, and by the rites you 
control them, there will be a sense of shame and of right.” The translation of 
this philosophy into cancer therapy in their research was described as 
“educating” cancer cells rather than killing them (Wang and Chen, 2008). This 
philosophy led to the introduction of all-trans retinoic acid (ATRA) in APL 
patients to induce terminal differentiation of the leukemic promyelocytes into 
mature granulocyte. Further development in this therapeutic strategy by 
applying arsenic trioxide (ATO) improved the clinical outcome of refractory or 
relapsed as well as newly diagnosed APL patients. The combination of ATRA 
and ATO demonstrated synergism in inducing differentiation and apoptosis 
turning this disease from highly fatal to highly curable (Coombs et al., 2015; 
Wang and Chen, 2008). 
 
1.5.3 PPARγ Ligands to Induce Benign Differentiation  
The success of ATRA inspired various attempts to induce differentiation in 
less differentiated solid tumours. The group of Professor Bruce Spiegelman 
demonstrated exciting results in various cancer types by manipulating the 
nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ).  
PPARγ is a ligand-activated transcription factor that plays an important role in 
a variety of physiological processes. PPARγ was initially characterized as the 
master regulator for adipogenesis but PPARγ signalling has also been 
implicated in the control of cell proliferation and metabolism. Ligands for 
PPARγ include naturally occurring fatty acids and a class of anti-diabetic 
drugs, the thiazolidinediones (TZD). The clinical benefit of these drugs in the 
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treatment of diabetes is mostly owing to the improvement of insulin sensitivity 
in these patients (Tontonoz and Spiegelman, 2008). 
PPARγ as a crucial transcription factor in adipocytes is also extensively 
present in malignancies of adipose tissue, liposarcoma (Tontonoz et al., 
1997). This observation led the authors to the hypothesis that treating 
transformed dedifferentiated cells of this tumour with TZD would induce a 
terminal differentiation into benign adipocytes and inhibit tumour progression, 
thanks to the post-mitotic characteristic of mature adipocytes. Preclinical and 
clinical experiments demonstrated a gain of adipocyte markers, reduced 
proliferation and typical adipocyte morphology in treated liposarcoma tumours 
(Demetri et al., 1999; Tontonoz et al., 1997). 
Surprisingly, Spiegelman and colleagues also observed high PPARγ 
levels in colon tumours, a cancer type originating from transformed epithelial 
cells. Thus, they tested the effect of TZD in colon cancer cells demonstrating 
here as well reduced cancer cell proliferation and increased differentiation. 
However, in this case the induced differentiation did not result in 
adipogenesis, but in a re-differentiation into colonic epithelial cells with 
decreased malignancy (Sarraf et al., 1998). 
Relatively high levels of PPARγ were also found in breast cancer 
metastasis. Here the combination of PPARγ agonists with a MEK inhibitor 
(PD98059) resulted in decreased proliferation and upregulation of epithelial 
markers (Mueller et al., 1998). 
Since this pioneer work on the effects of PPARγ ligands in cancer, 
multiple clinical studies in various cancer types were conducted. The majority 
of these studies were done in advanced stage disease and mostly as 
monotherapy using TZD. Yet, most of these studies did not show a significant 
clinical benefit (Hatton and Yee, 2008). 
Interestingly, the combination of PPARγ agonists with tyrosine kinase 
inhibitors in chronic myeloid leukaemia (CML) resulted in the erosion of the 
CSC pool by suppression of quiescence and stemness leading to long- term 
cancer cell eradication (Prost et al., 2015).  
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1.5.4 Inducing MET 
The concept of CSC in solid tumours and the relevance of EMT during 
malignant tumour progression evolved the induction of epithelial re-
differentiation as a possible therapeutic approach targeting specifically those 
cells. It is important to point out that such re-differentiation approaches require 
combination with chemotherapy or targeted therapies to achieve long-term 
clinical benefit (Pattabiraman and Weinberg, 2014).  
Mesenchymal invasive cells from mammary gland carcinomas were 
induced to undergo differentiation into epithelial cells by treatment with a 
histone deacetylase (HDAC) inhibitor called SAHA. Treatment with SAHA 
reduced proliferation and induced differentiation in these cells (Munster et al., 
2001).  A different HDAC inhibitor was shown to induce differentiation and to 
increase sensitivity to chemotherapy in EMT-derived pancreatic cancer cells 
(Meidhof et al., 2015). Indeed, during the last years numerous clinical trials 
with HDAC inhibitors have been performed for the treatment of different 
cancer types. However, HDAC inhibitors seem to have conflicting effects on 
regulating cell-state transitions, and the clinical results did not yet meet the 
expectations from this class of drugs (Tam and Weinberg, 2013). 
A recent study aimed at specifically inducing MET in breast cancer 
cells in order to overcome invasiveness and drug resistance correlating with 
EMT. Screening for compounds that induce the upregulation of CDH1 (the 
gene encoding for E-cadherin) revealed that the activation of adenylate 
cyclase (cAMP) could induce the acquisition of epithelial properties. The study 
further demonstrated a role for the cAMP-downstream effector protein kinase 
A (PKA) in inducing MET and maintaining an epithelial state (Pattabiraman et 
al., 2016). 
However, as emphasized above, cancer cell plasticity and the dynamic 
nature of EMT and MET during tumour dissemination and metastatic 
outgrowth underscore the possible weakness of epithelial differentiation. 
Although these processes are not fully understood, there is growing evidence 
that inducing MET may enhance metastatic outgrowth (Brabletz, 2012b; 
Pattabiraman and Weinberg, 2014). A further open question concerns the 
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ability of re-differentiated cells to undergo another round of EMT, a possible 
outcome that would endure plasticity response.  
 
1.5.5 Conclusion  
Forced differentiation as a therapeutic approach to specifically target EMT-
derived cells seems like addressing cancer cell plasticity in the same terms. 
However, a dedifferentiation potential remains in cells of epithelial origin and 
the rather plastic epithelial state could further allow tumorigenic phenotype. As 
discussed in the chapters about stem cells and iPSC, cell cycle plays an 
important role in the processes of differentiation and dedifferentiation. Cell 
cycle arrest keeps stem cells in their undifferentiated state (Orford and 
Scadden, 2008) as observed also in the case of dormant cancer stem cells 
(Massague and Obenauf, 2016). Moreover, cell cycle progression seems to 
play an important role in cellular reprogramming and a crucial step in 
generating iPS cells (Hanna et al., 2009). Hence, cell cycle arrest retains cells 
in their differentiated state and post-mitotic states could potentially inhibit 
processes of dedifferentiation.    
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1.6 Adipogenesis 
In the past, adipose tissue was considered a simple structure of connective 
tissue containing lipid droplets. Only recently the complexity of adipose tissue 
and its central role as an endocrine organ at the centre of energy homeostasis 
have been fully appreciated. The profound effect on pathophysiology of major 
metabolic disorders such as diabetes mellitus and obesity had placed adipose 
function and development in the focus of research and clinical interest (Rosen 
and Spiegelman, 2014). 
The epidemic disease of the modern society namely obesity and 
related metabolic disorders drew the attention to adult white adipose tissue 
(WAT). WAT has an important role in buffering nutrient availability and 
demand by storing excess calories and preventing the toxic accumulation of 
excess nutrients in non-adipose tissues. However, WAT is by no means a 
passive organ. WAT is able to communicate with metabolically relevant 
organs by secreting so-called adipokines as part of a dynamic endocrine 
system that regulates nutrient partitioning into peripheral tissues. Adipocyte-
secreted adipokines, such as leptin and adiponectin, have a central role in 
energy homeostasis and adipose tissue communication with other organs and 
the immune system (Peirce et al., 2014; Rosen and Spiegelman, 2014). 
However, the adult adipose organ also contains brown adipose tissue 
(BAT) whose main function is to maintain the core body temperature in 
response to cold stress by generating heat, a process known as 
thermogenesis. Like the uni-locular (single lipid droplet) white adipocytes in 
WAT, the multi-locular brown adipocytes in BAT also accumulate and store 
lipids. However, the highly specialized brown adipocytes are distinct from 
white adipocytes by more abundant mitochondria, which are enriched for the 
expression of uncoupling protein 1 (UCP1), enabling chemical energy storage 
in the form of heat (Peirce et al., 2014). 
Exposure to cold or activation of β-adrenergic receptor (β3) agonists 
that enhance lipolysis in adipocytes triggers the appearance of WAT 
browning, due to the generation of 'brown-like' fat cells, termed beige 
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adipocytes. Unlike classic brown adipocytes these beige adipocytes, do not 
derive from precursors that are positive for myogenic factor 5 (Myf5) (Peirce 
et al., 2014). Instead beige adipocytes seem to arise from de novo 
adipogenesis in WAT (Wang et al., 2013).  
In this chapter I will focus only on few aspects of this broad field of 
research, mainly on the most important issues regarding the process of 
adipogenesis and the general concepts of adipocyte characteristics.  
 
1.6.1 The Process of Adipogenesis 
During adipogenesis cells accumulate triglyceride, acquire the signet ring 
appearance of adipose cells, and ultimately lose their ability to revert to the 
growing state (Green and Kehinde, 1975). At the cellular level adipogenesis is 
defined as a two-phase process with an initial determination phase followed 
by the terminal differentiation to mature adipocyte (Farmer, 2006; Rosen and 
MacDougald, 2006; Rosen and Spiegelman, 2014). Determination requires 
commitment to the progressive adipogenesis transcriptional program in 
parallel to the suppression of alternate differentiation pathways, together 
resulting in the conversion of a stem cell to a pre-adipocyte (Rosen and 
MacDougald, 2006; Rosen and Spiegelman, 2014). A pre-adipocyte cannot 
be distinguished morphologically from its precursor cell, usually of 
mesenchymal origin, but has lost the potential to differentiate into other cell 
types (Rosen and MacDougald, 2006; Tontonoz and Spiegelman, 2008). 
Once committed to the adipogenic fate, a pre-adipocyte undergoes terminal 
differentiation and acquires mature adipocyte characteristics - including the 
machinery that is necessary for lipid transport and synthesis, insulin sensitivity 
and the secretion of adipocyte-specific proteins (Rosen and MacDougald, 
2006). Adipogenesis research developed mainly on the basis of in vitro 
cellular models that are already committed to the adipose lineage (e.g., 3T3-
L1, 3T3-F442A cells). Hence, much more is known about the later phases of 
adipogenesis and adipocyte terminal differentiation than about the cell fate 
decisions of a multipotent cell (Rosen and Spiegelman, 2014). 
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Most of the studies on pathways regulating cell fate between 
adipogenic and non-adipogenic commitment have been performed using 
bone-marrow-derived mesenchymal cells, and thus the “bone-fat switch” is 
the most commonly described fate choice. The activation of canonical and 
alternative Wnt signalling as well as of Hedgehog signalling tends to promote 
osteogenesis and to inhibit adipogenesis in both committed and uncommitted 
precursor cells (Park et al., 2015; Rosen and Spiegelman, 2014; Tang and 
Lane, 2012). The fate decisions via these pathways and others were partially 
linked to the regulation of YAP/TAZ transcriptional activity. YAP/TAZ activity is 
regulated by mechanical signals and have been shown to be the downstream 
effectors of, for example, the Hippo pathway (Halder et al., 2012) and 
alternative Wnt signalling (Park et al., 2015). Apart from YAP/TAZ 
transcriptional regulation of the osteogenic lineage, which in turn suppresses 
adipogenesis (Park et al., 2015), TAZ was shown to directly repress PPARγ-
dependent adipogenic gene transcription (Hong et al., 2005). The TGFβ 
family has also a profound effect on adipogenic commitment and progression 
and will be discussed in the next chapter on TGFβ signalling. 
The principle pathway of adipogeneis involves the activation of 
CCAAT-enhancer binding protein β and δ (C/EBPβ, C/EBPδ) which facilitate 
the upregulation of PPARγ and C/EBPα, the master regulators of 
adipogenesis (Farmer, 2006).  Different mechanisms have been suggested 
for the initial activation of C/EBPβ (Gubelmann et al., 2014). Nuclear receptor 
corepressor 2 (NCoR2), also known as silencing mediator of retinoic acid and 
thyroid hormone receptor (SMRT), is an interesting example acting as a gate-
keeper of adipognesis by masking C/EBPβ enhancers (Raghav et al., 2012). 
Krüppel-like factor 4 (Klf4) was shown to be necessary for adipogenesis by 
directly activating C/EBPβ, which in turn supresses Klf4 via a tightly controlled 
negative feedback loop (Birsoy et al., 2008). As described in the latter study, 
C/EBPβ has a regulatory effect on adipogenesis activating factors. A recent 
study identified Zeb1, an EMT-transcription factor (see Box1), as a central 
regulator of adipogenesis acting in conjunction with C/EBPβ. Zeb1 is bound to 
open/activate gene regulatory regions before the onset of adipogenesis in 
committed pre-adipocytes, many of which are targeted by first-wave 
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adipogenic transcriptions factors, especially by C/EBPβ (Gubelmann et al., 
2014). 
This transcriptional initiation of adipogenesis results in the expression 
of the downstream targets and adipogenesis master regulators PPARγ and 
C/EBPα. PPARγ is both necessary and sufficient for adipogenesis. Hence, 
PPARγ is such a potent adipogenic factor that its ectopic expression can drive 
non-adipogenic fibroblasts to become adipocytes (Rosen and Spiegelman, 
2014). Murine studies demonstrated that PPARγ is essential for adipose 
tissue formation (Farmer, 2006). In agreement with these results, humans 
with rare loss-of-function mutations in PPARγ exhibit lipodystrophy and 
severe insulin resistance (Rosen and Spiegelman, 2014). C/EBPα is also 
required for adipogenesis, and its absence impairs adipose tissue formation. 
However, C/EBPα is not sufficient to induce adipogenesis, if PPARγ is 
absent, whereas PPARγ can activate adipogenesis even in C/EBPα-deficient 
cells (Farmer, 2006). Once activated, adipogenesis is then “locked in” by a 
positive feedback loop between PPARγ and C/EBPα; a second positive 
feedback loop between PPARγ and C/EBPβ reinforces the decision to 
differentiate (Rosen and Spiegelman, 2014). 
Alternative splicing is responsible for the generation of two protein 
isoforms of PPARγ. PPARγ2 has an additional 30 amino acids at its N-
terminus as compared to PPARγ1 and is more specific for adipose tissue. 
Genetic mouse models demonstrate that PPARγ1 has adipogenic action, 
although PPARγ2 appears more potent in this function (Tontonoz and 
Spiegelman, 2008).  
PPARγ is a nuclear receptor that acts as ligand-gated transcription 
factor (Tontonoz and Spiegelman, 2008). Fatty acids and their derivatives can 
bind and activate PPARγ, however the identification of specific endogenous 
PPARγ ligands has been widely unsuccessful. In contrast, synthetic ligands, 
such as TZDs have been identified as specific PPARγ ligands with a well-
studied mechanism of activation. TZDs, such as rosiglitazone and 
pioglitazone, are potent activators of PPARγ with robust insulin-sensitizing 
activities and are highly effective oral medications used in the treatment of 
difficult-to-manage type 2 diabetes (Ahmadian et al., 2013). TZD regulation of 
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PPARγ is two-fold, since these agonists are capable not only to activate 
PPARγ and initiate adipogenesis, but also to protect PPARγ against 
phosphorylation. The second mechanism is directly responsible for the insulin 
sensitizing effect of these compounds (Banks et al., 2015). 
PPARγ and C/EBPα act as transcription factors of a large number of 
genes responsible for adipocytes formation and function including fatty acid 
binding protein 4 (FABP4), the adipokine adiponectin and the insulin-sensitive 
glucose transporter 4 (GLUT4). Indeed, PPARγ is also necessary for 
adipocyte maintenance as demonstrated in vitro and in vivo (Tontonoz and 
Spiegelman, 2008). 
As mentioned above, ectopic expression of PPARγ in non-adipogenic 
cells, such as fibroblasts, is sufficient to induce adipogenesis (Rosen and 
Spiegelman, 2014). However, the activation of adipogenesis with TZD via 
endogenous PPARγ alone is not enough for effective adipogenesis even in 
pre-adipocytes (Hong et al., 2005). Moreover, PPARγ activation in other cell 
types expressing this receptor, such as colon epithelial cells, does not result 
in adipogenesis (Rosen and MacDougald, 2006; Sarraf et al., 1998). These 
results demonstrate the complex signalling networks orchestrating 
adipogenesis progression even in adipocyte-primed cellular states.  
 
1.6.2 Growth Arrest 
Adipogenesis is classically induced in a confluent population of preadipocytes 
by exposure to insulin, inducers of cAMP signalling and glucocorticoids in 
serum-complemented medium. The cells are then induced to re-enter cell 
cycle and undergo at least one round of clonal expansion before proceeding 
into terminal differentiation (Farmer, 2006).  
In pre-adipocytes, growth arrest and not cell confluence or cell-cell 
contact per se appears to be required for adipocyte differentiation as 
demonstrated by the differentiation of re-seeded confluent 3T3-F442A cells in 
suspension. Furthermore, primary rat pre-adipocytes plated at low density in 
serum-free medium were also able to differentiate in the absence of cell-cell 
contact (Gregoire et al., 1998). 
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Both adipocyte regulators C/EBPα and PPARγ appear to be critical for 
the growth arrest that is required for adipocyte differentiation. Both 
transcription factors’ activation and expression mediate the upregulation of 
cyclin-dependent kinase inhibitors, thereby providing a molecular mechanism 
coupling growth arrest and adipocyte differentiation (Gregoire et al., 1998; 
Morrison and Farmer, 1999). One study indicated that the cell cycle block in 
3T3-L1 cell adipogenic differentiation occurs despite high levels of c-Myc and 
hyperphosphorylated Retinoblastoma (Rb) (Reichert and Eick, 1999). Cell-
cycle proteins of the E2F family of transcription factors and associated pocket 
proteins seem to have a regulatory role in adipogenesis. E2F transcription 
factors and pocket proteins seem to regulate two separate but parallel 
pathways that result in the activation of PPARγ1 and PPARγ2 expression. 
Factors such as Rb which activates C/EBPβ promotes PPARγ2 production, 
whereas factors that induce E2F1 activity support PPARγ1 expression. Since 
PPARγ2 and not PPARγ1 is considered to be the predominant regulator of 
adipogenesis, factors such as E2F may lead to C/EBPα expression induced 
by PPARγ1 which in turn enhances PPARγ2 expression (Farmer, 2006). 
The simultaneous regulation of cell cycle and adipogenic regulators 
eventually results in cell cycle exit and the generation of terminally 
differentiated-postmitotic adipocytes (Wang et al., 2013).  
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1.7 TGFβ-Signalling in Plasticity and Differentiation 
Polyphenism, as described for the black tobacco hornworm in the first part of 
the introduction (See chapter: Polyphenism – Organism Plasticity) implies the 
central role of signal variations in plasticity induction. The contribution of 
microenvironmental stimuli to stem cell function and cancer plasticity was 
discussed thereafter. Different signalling pathways were briefly mentioned in 
this context, including TGFβ signalling. TGFβ signalling has been proven 
central in various processes such as proliferation, differentiation, and cancer 
invasion, specifically in EMT. The thought that plasticity and perhaps cancer 
malignancy per se may be substantially influenced by cell extrinsic factors is 
intriguing. In this part, I specifically discuss TGFβ signalling as a paradigm to 
the above-mentioned premise.  
TGFβ’s effect on cellular response has been described as context-
dependent (Massague, 2012). Intriguingly, TGFβ family members are able to 
target just a few genes in pluripotent ES cells but hundreds of genes in 
differentiated cells. Hence, TGFβ can activate or inhibit transcription 
depending on the targeted gene and the cellular context. For example, in 
mammary epithelial cells TGFβ represses inhibitor of differentiation 1 (ID1) 
but induces this gene in metastatic breast cancer cells. 
Three types of contextual determinants are defined to shape the TGFβ 
transcriptional response. First, the epigenetic landscape of the cell modifies 
the chromatin and dictates which genes are open for expression and thus 
susceptible to regulation. For example, ESC maintain pluripotency genes in 
an open chromatin conformation that permits transcriptional activation 
downstream of TGFβ signals, whereas genes involved in differentiation 
remain repressed and refractory to these inputs. When conditions are 
permissive for ESC differentiation, specific chromatin marks open master 
differentiation genes to their activation by the TGFβ family member NODAL, 
which regulates pluripotency and differentiation.  
A second determinant of TGFβ target gene regulation is the availability 
of SMAD- TGFβ signalling effectors or other transcription co-factors. The third 
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determinant described refers to extracellular and intracellular composition of 
the TGFβ signal transduction system. The intensity of the TGFβ signal is the 
result of this system and determines the response by regulating SMAD 
function or activating non-canonical TGFβ pathways. Inputs that affect the 
intensity of the TGFβ signal may qualitatively influence the cellular response 
as observed in cell fate decisions. These emerge from fine-tuned gradients of 
BMP acting alongside WNT and Hedgehog signals during development 
(Massague, 2012). 
The TGFβ pathway is indeed essential for developmental processes, 
including mesoderm specification and dorsal–ventral axis formation, and is 
dysregulated in a variety of cancers. The TGFβ superfamily acts via canonical 
(SMAD- mediated) and non-canonical signal transductions that orchestrate 
the function and balance of this pathway.  
One example for the contextual role of the TGFβ superfamily refers to 
the function of the secreted BMP inhibitor COCO in development and disease. 
Deglincerti and co-workers focused on the canonical TGFβ pathway, which 
consists of two branches (Deglincerti et al., 2015). TGFβ/activin/nodal ligands 
signal through type1 receptors Alk4/5/7 to induce the phosphorylation of 
Smad2/3, BMPs activate Smad1/5/8 via Alk1/2/3/6 receptors. Phosphorylation 
of the receptor-activated Smads (R-Smads) from either branch of the pathway 
results in complex formation with Smad4 and its nuclear translocation. Smad4 
localization upon TGFβ pathway activation was used as a reporter system to 
monitor TGFβ1 signalling dynamics and response. The Smad4 localization 
reporter was previously published by the same group (Warmflash et al., 2012) 
and was used in this paper to study the molecular mechanisms regulating the 
rapid TGFβ1 response by combining it with a genome-wide RNAi screen. 48 
hours after RNAi library transfection, mouse myoblast C2C12 GFP-Smad4 
reporter cells were stimulated with TGFβ1. Cells were fixed and analysed at 
the peak Smad4 nuclear translocation time point (1 hour after stimulation) to 
study genes that prevent GFP-Smad4 nuclear localization as well as 6 hours 
after stimulation to study genes that prevent its return to the cytoplasm. 321 
genes were shown to significantly affect GFP-Smad4 localization.  
TGFβ-signalling in Plasticity and Differentiation Introduction 
 
47 
Among these genes the authors identified the secreted protein Coco 
(Dand5), which is known to inhibit BMP4 and Nodal. Surprisingly, the authors 
observed that the RNAi-mediated ablation of Coco expression impaired GFP-
Smad4 nuclear localization. Further investigation of Coco’s effect on TGFβ1 
signalling by various knockdown and overexpression experiments 
demonstrated an enhancing effect of Coco on TGFβ1 signalling accompanied 
by the known inhibitory effect of Coco on BMP4. The authors further 
demonstrate that Coco directly enhances the interactions of TGFβ1 and its 
receptor Alk5. 
The implication of Coco as both an inhibitor and enhancer of TGFβ 
pathway depending on the ligand it interacts with may explain its critical 
function in development but also in disease as a possible enhancer of cancer 
metastasis. Coco was also identified as an activator of lung metastasis 
outgrowth in mouse breast cancer model (Gao et al., 2012b). These authors 
demonstrated that Coco promoted the exit from dormancy by alleviating the 
ability of lung- stromal BMP to enforce a dormant state.  
Taken together these studies suggest that Coco can have one effect 
on microenvironmental signals and an opposing effect on invasive cancer 
cells during metastasis. 
 
1.7.1 TGFβ-Signalling in EMT and MET 
TGFβ induces EMT during heart development, palate fusion and renal 
fibrosis, as well as in breast and hepatic epithelial cells (Massague, 2012). 
TGFβ directly regulates EMT-related transcription factors, such as Snail, 
Twist and Zeb (Xu et al., 2009). BMPs, which are known to induce miR-200 
and miR-205 are considered inhibitors of an EMT and activators of a MET 
process (Massague, 2012). However, BMP4 together with Wnt1 induces 
neural crest delamination during development, a process that shares 
transcriptional and molecular similarities with EMT and also resulting into a 
migratory phenotype (Theveneau and Mayor, 2012).  
TGFβ induces EMT by canonical SMAD activation but also elicits 
signalling responses through pathways that are generally considered as 
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important effector pathways for tyrosine kinase receptors in response to 
ligands that do not belong to the TGFβ family. These non-canonical signalling 
pathways are rapidly activated by TGFβ and often follow similar kinetics as 
SMAD signalling. Attenuation of SMAD signalling does not generally affect the 
activation of these pathways. Non-canonical signalling responses to TGFβ 
can also occur with delayed kinetics and are then often indirect, presumably 
as a result of SMAD-mediated changes in gene expression. The direct 
activation of non-SMAD signaling pathways by TGFβ occurs through 
interactions of signalling mediators either directly with the TβRII and/or TβRI 
receptors or through adaptor proteins. Among the non-canonical signalling 
responses, activation of MAP kinases, MEK and ERK kinases, Rho GTPases 
and the PI3 kinase/Akt pathway have been linked to TGFβ-induced EMT 
through their regulation of distinct processes, such as cytoskeleton re-
organization, cell growth, survival, migration and invasion (Xu et al., 2009). 
 
1.7.2  TGFβ Family Members in Adipogenesis 
BMPs usually show a minor effect on pre-adipocyte differentiation. However, 
exposure of multipotent mesenchymal cells to BMP4 commits these cells to 
the adipocyte lineage, allowing them to undergo adipogenesis (Rosen and 
MacDougald, 2006). BMP2 seems to promote osteogenesis by upregulating 
TAZ expression (Hong et al., 2005). However, when combined with 
adipogenic inducers, BMP2 activates adipogenesis in multipotent cells 
(Gubelmann et al., 2014). While BMP2 and BMP4 enhance white 
adipogenesis, BMP7 is a potent inducer of brown adipocyte differentiation 
(Tseng et al., 2008). 
Indeed, TGFβ signalling is found activated in mature adipocytes and 
adipose tissue. However, TGFβ inhibits adipogenesis and impairs the 
development of adipose tissue. Inhibiting endogenous TGFβ signalling by 
either expressing dominant-negative TGFβ receptor or by direct inhibition of 
SMAD3 lead to increased adipogenesis. SMAD3 was found to bind to C/EBPs 
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and to inhibit their transcriptional activity, including their ability to activate 
PPPARγ2 expression (Rosen and MacDougald, 2006). 
TGFβ-mediated inhibition of adipogenesis is usually linked to its 
canonical signalling. However, ERK has been previously reported to interfere 
with PPARγ function leading to obesity-linked insulin resistance (Rosen and 
MacDougald, 2006). ERK directly phosphorylates PPARγ at serine 273 in a 
robust manner and induces diabetogenic gene expression in adipose tissues 
(Banks et al., 2015). Moreover, in the terminal differentiation phase, ERK1 
phosphorylation of PPARγ inhibits differentiation (Rosen and MacDougald, 
2006). Surprisingly, TGFβ activation of ERK as a possible mechanism for the 
blockade of adipogenesis by TGFβ has never been demonstrated.
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2 Aim of the study 
Cancer is a systemic heterogeneous disease that can undergo several rounds 
of latency and activation. Malignant tumours evolve by increasing diversity 
and in progressive response to microenvironment signals and therapeutic 
interventions. Hence, both cancer diversity and cellular plasticity contribute to 
cancer progression and thus are an obstacle for cancer therapy (Figure 3 in 
the introduction).  
 New therapeutic approaches and drugs targeting cancer cells are 
constantly developed; some of which target cancer cell hyperproliferation, 
others target specific signalling pathways mutated and/or hyperactivated in 
cancer cells, and still others aim to specifically eliminate or inhibit cancer stem 
cells. Yet, in many cancer types, including breast cancer, the therapeutic 
success remains limited making cancer recurrence and metastatic outgrowth 
a frequent clinical event. 
 Cancer plasticity may possibly explain cancer progression regardless 
of the therapeutic approach. Processes like EMT and MET enable tumour 
cells to elude a hostile microenvironment and to develop drug resistance. 
Such plasticity induced dynamic changes are contemporaneous to the 
differentiation state of the cell and are plausible in both a well-differentiated 
cancer cell and in a cancer stem cell (See Figure 2 in Introduction).   
In my studies, I have aimed at utilizing cancer cell plasticity by inducing 
their terminal differentiation into postmitotic adipocytes. Adipocytes are 
specialized robust cells; given their inherent growth arrest they are unlikely to 
adapt and dedifferentiate. Thus these are cells whose intra-cellular plasticity is 
inhibited. Since they are non-proliferative, many of the typical cancer 
mutations may become irrelevant in adipocytes.   
 By targeting cancer cell plasticity to force trans-differentiation into 
adipocytes we may be able to disarm malignant tumours both from their 
diversity and from their cellular plasticity. If such a conversion will be proved 
possible, we can potentially transform malignant tumours into a benign 
phenotype.   
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3.1  Abstract 
A high degree of cell plasticity seems to promote malignant tumour 
progression, and an epithelial-mesenchymal transition (EMT) is 
suspected to provide cancer cells with increased cell plasticity for the 
development of metastasis and therapy resistance. Here, we have tested 
whether the EMT-induced cancer cell plasticity can be therapeutically 
exploited and we report the efficient conversion of breast cancer cells, 
which have undergone an EMT, into post-mitotic adipocytes. Delineation 
of the molecular pathways underlying such transdifferentiation has 
motivated a combination therapy with a MEK inhibitor and Rosiglitazone 
to demonstrate the conversion of invasive cancer cells into adipocytes 
and the repression of primary tumour invasion and metastasis formation 
in mouse models of breast cancer. The results indicate the high 
potential that lies in the increased cell plasticity of invasive cancer cells 
for differentiation therapy and they raise the possibility of 
pharmacological interference with tumour invasion and metastasis.  
 
3.2  Introduction 
Cancer cell plasticity plays a critical role in cancer cell survival, invasion and 
metastasis formation (Massague and Obenauf, 2016), as well as in tumour 
heterogeneity (Koren et al., 2015; Van Keymeulen et al., 2015) and in the 
development of therapy resistance (Holohan et al., 2013; Jordan et al., 2016). 
Cancer cell plasticity is of a dynamic nature and can be the result of changing 
cues in the microenvironment (Oshimori et al., 2015). An epithelial-
mesenchymal transition (EMT) seems to play a major role in facilitating cell 
plasticity in cancer and allows cancer cells to escape chemotherapies and 
targeted therapies by dedifferentiation and signalling adaption processes 
(Fischer et al., 2015; Gao et al., 2012b; Labelle et al., 2011; Valiente et al., 
2014; Zheng et al., 2015). While an EMT is mainly responsible for primary 
tumour cell invasion, its reversal, a mesenchymal-epithelial transition (MET), 
has been shown to contribute to the metastatic outgrowth of disseminated 
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cancer cells in distant organs (Ocana et al., 2012; Tsai et al., 2012). Hence, 
the therapeutic reversion of an EMT could be counterproductive (Nieto, 2013). 
However, it has also been noted that cells undergoing an EMT and/or an MET 
are in a state of high cell plasticity and thus may offer a window of opportunity 
for therapeutic targeting (Brabletz, 2012a; Gupta et al., 2009; Nieto, 2013; 
Nieto et al., 2016).  
The observation that cell dedifferentiation processes in cancer are 
often correlated with increased malignancy and cancer-initiating potential 
(Lawson et al., 2015; Oshimori et al., 2015; Tam and Weinberg, 2013) has 
readily lead to the appealing strategy of treating malignancies by inducing 
cancer cell differentiation. While attempted already in 1959 as a possible 
treatment for teratoma (Pierce and Dixon, 1959), a prominent example of a 
highly successful differentiation therapy has been the introduction of all-trans 
retinoic acid (ATRA) as a therapy for Acute Promyelocytic Leukemia (APL) 
(Wang and Chen, 2008). In carcinomas, therapeutic approaches to revert 
dedifferentiated cancer cells into normal epithelial cells have reduced cell 
proliferation and increased the sensitivity to chemotherapy (Girnun et al., 
2007; Mueller et al., 1998; Wielenga et al., 2015). However, the dynamic 
nature of the processes underlying cell plasticity may explain the limited 
clinical benefit of epithelial re-differentiation therapy. 
 
3.3  Results 
3.3.1 EMT-Breast Cancer Cells Convert into Adipocytes 
We set out to assess whether the cell plasticity of cancer cells acquired by an 
EMT can be exploited to force their transdifferentiation into cells with benign 
traits, such as adipocytes. Adipocytes represent an ideal cell type for a benign 
trans-differentiation of malignant entities; they are usually benign and they 
present features of terminal differentiation and post-mitotic cell cycle arrest.  
As cellular models of EMT-induced cancer cell plasticity we used Py2T 
murine epithelial breast cancer cells that undergo a reversible EMT upon 
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induction with transforming growth factor β (TGFβ) in vitro and gain 
mesenchymal characteristics when implanted into mice in vivo (Waldmeier et 
al., 2012). Py2T-LT cells are Py2T cells that have been treated with TGFβ for 
at least 20 days to induce a complete EMT program. As a second 
experimental system, we have used epithelial MTflECad murine breast cancer 
cells which carry floxed alleles of the E-cadherin gene (Cdh1) and undergo an 
EMT upon Cre-mediated genetic ablation of the E-cadherin gene (MTΔECad 
cells). They represent an irreversible EMT model of murine breast cancer 
cells with demonstrated cancer stem cell characteristics (Fantozzi et al., 
2014).   
We first optimized an adipogenesis protocol in 3T3-L1 pre-adipocytes 
which are well-known to differentiate into adipocytes when induced with 
insulin, Dexamethasone and Rosiglitazone (a potent ligand of peroxisome 
proliferator-activated receptor γ (PPARγ) (Gubelmann et al., 2014; Hong et al., 
2005) (Fig. 1a). For the induction of adipogenesis in breast cancer cells, this 
protocol was combined with bone morphogenetic protein-2 (BMP2), as 
suggested for multipotent mesenchymal stem cell differentiation (Gubelmann 
et al., 2014; Tseng et al., 2008). The generation of bona fide adipocytes was 
first assessed by staining with fluorescent Nile Red to visualize lipid droplets. 
The accumulation of lipid droplets was readily detected in both mesenchymal 
breast cancer cells but not in their epithelial counterparts (Fig. 1a). C/EBPα is 
a master regulator of adipogenesis and is expressed in the pre-adipocytic cell 
line 3T3-L1 when undergoing adipogenesis. Immunofluorescence analysis 
showed the presence of C/EBPα in mesenchymal Py2T-LT and MTΔECad 
cells. The expression of C/EBPα could not be detected in epithelial Py2T or 
MTflECad cells treated with the identical differentiation protocol (Fig. 1a). 
C/EBPβ, an early regulator of adipogenesis and gatekeeper of the adipogenic 
lineage determination (Raghav et al., 2012), was found absent in untreated 
and treated epithelial MTflECad cells, yet already expressed in untreated as 
well as in treated MTΔECad mesenchymal cells (Extended Data Fig. 1a). 
Our main goal was to use adipogenesis of malignant cancer cells as a 
therapeutic option. Thus, we aimed at reducing the treatment protocol to a 
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minimal number of pharmaceutical compounds. In a minimal factor scenario, 
we were able to induce adipogenesis in mesenchymal breast cancer cells with 
Rosiglitazone alone at a concentration of 2µM. The efficiency of adipogenesis 
was further enhanced when combining Rosaglitazone with BMP2. Thus, all in 
vitro experiments described hereafter were performed using these two 
compounds, unless stated otherwise. 
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Figure 1. Mesenchymal murine breast cancer cells can be induced to 
differentiate into functional adipocytes and to lose malignant characteristics.  
(a) Fibroblastic pre-adipocytes (3T3-L1) were treated with insulin, Dexamethasone 
and Rosiglitazone to induce adipogenesis. Mesenchymal (MTΔEcad and Py2T-LT; 
mes) and epithelial (MTflEcad and Py2T; epi) cancer cells were treated with insulin, 
Dexamethasone, Rosiglitazone and BMP2 to induce adipogenesis. Lipid droplets 
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were visualized by immunofluorescence microscopy with Nile Red (red), the 
adipogenesis regulator C/EBPα by a specific antibody (green), and nuclei by DAPI 
(blue).  
(b) MTΔEcad cells were treated with Rosiglitazone and BMP2 (Treated) or DMSO 
solvent (Control) to induce adipogenesis. The adipogenesis regulator PPARγ (green), 
Phalloidin (F-actin, red) and nuclei (DAPI) were visualized by immunofluorescence 
staining.  
(c) Control and Rosiglitazone/BMP2-treated MTΔECad cells were stimulated with 
insulin for 25 minutes to induce GLUT4 translocation to the plasma membrane. 
GLUT4 (green) and DAPI (blue) were visualized by immunofluorescence staining 
and confocal microscopy.  
(d, e) Control and Rosiglitazone/BMP2-treated MTΔECad cells were incubated with 
EdU for 72 hours to quantify proliferating cells. Representative images of EdU 
staining (green) and DAPI staining are shown (blue) (d). EdU intensities were 
quantified using Image J. The graph shows means ± SEM; unpaired Student’s t-test; 
**P =0.001 (e).  
Scale bar, 100µm. 
 
 
To further characterise the cancer cells undergoing adipogenesis we 
analysed their expression of mesenchymal and adipocyte-specific markers. A 
continuous increase in the expression of the adipogenesis master regulator 
PPARγ and of the adipokine produced by mature adipocytes, Adipoq, were 
detected by quantitative RT-PCR (Extended Data Fig. 1b) and by 
immunofluorescence microscopy analysis of differentiated cells (Extended 
Data Fig. 2a,b). Immunofluorescence microscopy analysis further showed the 
down-regulation of alpha-smooth muscle actin (αSMA) expression in 
differentiated adipocytes, a further sign for the immobilization and 
differentiation status of the cells (Extended Fig. 2a). Visualisation of the actin 
cytoskeleton by Phalloidin staining revealed a reorganization of mesenchymal 
stress fibres into cortical actin, a hallmark of cell immobilization, in both 
mesenchymal cell lines, even in the absence of E-cadherin expression in 
MTΔECad cells (Fig. 1b and Extended Data Fig. 2b). We further tested the 
functionality of the transdifferentiated adipocytes by inducing translocation of 
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the insulin-sensitive glucose transporter GLUT4 which is usually expressed in 
adipocytes, muscle cells and cardiomyocytes. MTΔECad cells were induced 
to undergo adipogenesis and then stimulated with insulin to activate GLUT4 
translocation to the plasma membrane. Indeed, GLUT4 expression was 
increased in differentiated cells and differentiated cells responded to insulin 
stimulation by GLUT4 translocation to the plasma membrane (Fig. 1c).  
As mentioned above, when considering cancer therapy, one of the 
most appealing characteristics of adipocytes is their cell-cycle arrest. We thus 
assessed the cell cycle status of transdifferentiated mesenchymal breast 
cancer cells. Adipogenesis-induced MTΔECad were incubated with EdU for 
72 hours to quantify proliferating cells. The results revealed a significant 
decrease in proliferation of transdifferentiated adipocytes (Fig. 1d,e). 
Immunoblotting analysis also demonstrated the downregulation of 
phosphorylated histone 3 (pH3) and of cyclin D1, additional markers of cell 
proliferation (Extended Data Fig. 2c).  
YAP and TAZ play a central role in tissue homeostasis, organ size 
regulation and tumourigenesis (Halder et al., 2012; Moroishi et al., 2015). 
YAP/TAZ transcriptional activation upon translocation to the nucleus induces 
cell proliferation and EMT (Diepenbruck et al., 2014; Moroishi et al., 2015). 
YAP/TAZ regulate also stem cell maintenance and differentiation and were 
shown to induce osteogenesis and inhibit adipogenesis in multipotent 
mesenchymal stem cells (Halder et al., 2012; Hong et al., 2005). YAP/TAZ 
cellular localization was visualized during MTΔECad- adipogenesis time 
course. During the same time course, cells were incubated with Edu for 24 
hours to detect proliferating cells. The data demonstrates a progressive 
translocation and downregulation of YAP/TAZ expression during 
adipogenesis. As expected, YAP/TAZ translocation to the cytoplasm 
correlated with proliferation decrease (Supplementary Data Fig. 1).  
Replacing the differentiation medium by normal culture medium for 7 
days after differentiation treatment and subsequent Nile Red staining showed 
that differentiated cells did not revert to an epithelial or mesenchymal state 
and maintained the typical adipocyte morphology (Supplementary Data Fig. 
2). These data demonstrate that breast cancer cells undergoing an EMT gain 
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the potential to irreversibly differentiate into bona fide adipocytes with post-
mitotic cell cycle arrest. Epithelial cancer cells lack this transdifferentiation 
potential, supporting the notion that an EMT coincides with increased cell 
plasticity.  
 
3.3.2 Multi-Differentiation Potential  
We next assessed whether the potency of EMT-derived breast cancer cells 
includes the ability to differentiate into further cell types of the mesenchymal 
lineage, such as osteoblasts and chondrocytes. MTΔECad cells were treated 
with differentiation protocols adapted from previous reports about multipotent 
mesenchymal cell differentiation to induce osteogenesis and chondrogenesis 
(Karamboulas et al., 2010; Mackay et al., 1998; Pittenger et al., 1999). 
Immunofluorescence microscopy analysis showed the presence of the 
osteoblast regulator, Osterix in osteogenesis-induced cells (Fig. 2a). 
Chondrogenesis-induced cells expressed Sox9, a master transcription factor 
of chondrogenesis, and chondrocyte-secreted collagen type 2 (Col2) (Fig. 
2b). However, we did not optimize the protocols used in these experiments to 
achieve higher efficiency, since the therapeutic potential seemed less 
promising compared to adipogenesis of mesenchymal breast cancer cells. 
Nevertheless, the results underscore the high cell plasticity and 
transdifferentiation potential of breast cancer cells that have undergone an 
EMT.  
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Figure 2: EMT-derived murine breast cancer cells show multi-cell type 
differentiation potential.  
(a) Osteogenesis was induced in MTΔECad cells for 21 days (Treated D 21). The 
osteoblast-specific transcription factor Osterix (green) was visualized by 
immunofluorescence staining.  
(b) Chondrogenesis was induced in MTΔECad cells for 21 days (Treated D 21). The 
chondrocyte transcription factor SOX9 (red) and cartilage-characteristic type II 
collagen (Col2, green) were visualized by immunofluorescence staining. Scale bars, 
100µm. 
 
3.3.3 MEK Inhibition Promotes Adipogenesis  
As previously reported, BMPs play a major role in inducing adipogenesis and 
are inducers of a MET (Samavarchi-Tehrani et al., 2010; Suenaga et al., 
2013). On the other hand, TGFβ acts as an inhibitor of this differentiation 
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process, yet is one of the most potent inducers of an EMT, and TGFβ-
signalling pathways are activated in metastatic cancer cells (Bruna et al., 
2012; Oshimori et al., 2015). Indeed, the presence of TGFβ during the 
induction of adipogenesis repressed efficient adipogenesis of MTΔECad cells, 
while the inhibition of TGFβ signalling with a pharmacological inhibitor 
(SB431542) promoted adipogenesis (Fig. 3; Extended Data Fig. 2b,c). To 
overcome TGFβ-mediated inhibition of adipogenesis, we inquired which of the 
TGFβ-induced pathways was responsible for this inhibition. Immunoblotting 
analysis identified the non-canonical MEK/ERK pathway as the major inhibitor 
of adipogenesis in cancer cells (Fig. 3a). Other canonical (pSMAD2, 
pSMAD3) and non-canonical (pTAK1, pP38) TGFβ signalling pathways did 
not show a direct correlation with adipogenesis of mesenchymal breast 
cancer cells (data not shown). ERK has been previously reported to interfere 
with PPARγ function leading to obesity-linked insulin resistance (Banks et al., 
2015). We thus tested whether inhibition of the MEK/ERK non-canonical 
TGFβ signalling pathway was able to overcome TGFβ-mediated inhibition of 
adipogenesis. Indeed, pharmacological inhibition of MEK activation with the 
MEK inhibitor (MEKi) PD98059 allowed the differentiation of mesenchymal 
cancer cells even in the presence of TGFβ as demonstrated by 
immunoblotting of adipocyte marker expression and Nile Red staining 
analysis (Fig. 3a-c).  
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Figure 3. Inhibition of MEK facilitates adipogenesis under TGFβ  treatment. 
(a, b, c) MTΔECad cells were treated with Rosaglitazone and BMP2 (Control) and in 
addition with TGFβ, the TGFβ receptor inhibitor SB431542, and the MEK inhibitor 
(MEKi) PD98059 as indicated. After 7 days, the levels of phosphorylated ERK1/2 (P-
ERK1/2) and total ERK (ERK1/2) as well as PPARγ1/2 were determined by 
immunoblotting analysis (a). After 7 days, phase contrast microscopy images were 
taken (b) and, after ten days, lipid droplets and nuclei were visualized by 
immunofluorescence Nile Red and DAPI stainings (c), Scale bars, 100µm. 
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3.3.4 Forced Adipogenesis Inhibits Tumour Invasion and Metastasis  
Overcoming the known TGFβ-mediated inhibition of adipogenesis motivated 
us to test our hypothesis in vivo. In a first proof-of-concept study, we 
transplanted GFP-expressing Py2T murine breast cancer cells, known to 
undergo EMT in vivo (Waldmeier et al., 2012), into the mammary fat pad of 
female RAG2-/-;common γ receptor -/- (RSG) mice. After an initial growth of 
the primary tumours, mice were divided into three groups with the following 
treatment protocols of two weeks: a control group treated with vehicle alone, a 
low treatment group treated with 16mg/kg Rosiglitazone and 2mg/kg MEKi 
PD98059, and a high treatment group treated with 16mg/kg Rosiglitazone and 
5mg/kg MEKi PD98059. After termination of the treatment, the expression of 
the adipocyte markers Adipoq and Fatty acid binding protein 4 (FABP4) was 
found significantly increased in tumours of Rosaglitazone/MEKi-treated mice 
(Extended Data Fig. 3a). Interestingly, there was no significant change in the 
tumour mass between the treatment groups (Extended Data Fig. 3b), 
although MEK inhibition was anticipated to exert an inhibitory effect on cell 
proliferation.  
We next assessed whether the up-regulation of adipocyte markers is 
due to generally increased adipogenesis in the tumour stroma or due to the 
cancer cells’ direct transdifferentiation into adipocytes. Lipid droplets 
accumulating within cells of tumour sections were visualized with red BODIPY 
dye and tumour cells were identified by GFP expression. Strikingly, many of 
the lipid droplets-containing cells in the tumours of Rosaglitazone/MEKi-
treated mice expressed GFP and, thus originated from transplanted cancer 
cells. As a control for this co-localization between GFP and BODIPY we 
specifically searched for adipocytes in control-treated tumours. Here, the 
adipocytes of the mammary fat pad were negative for GFP (Extended Data 
Fig. 3c-e).  
We next asked whether the direct differentiation of breast cancer cells 
into adipocytes might inhibit the metastatic dissemination or metastatic 
outgrowth of invasive cancer cells. ZsGreen-expressing 4T1 murine 
metastatic breast cancer cells were injected into the mammary fat pad of 
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immune-deficient nu/nu mice. After initial primary tumour growth, mice were 
divided into two treatment groups. The control group was treated with vehicle 
alone, and the experimental group was treated with 16mg/kg Rosiglitazone 
and 2mg/kg MEKi PD98059 for 17 days. Monitoring primary tumour growth in 
the individual mice showed that the primary tumours in the treatment group 
grew slower than in the control group, and primary tumour mass was 
significantly lower in treated mice upon termination of the experiment 
(Extended Data Fig. 4a,b).  
To identify labelled tumour cells that had differentiated into adipocytes, 
tumour sections were stained with red BODIPY to visualize lipid droplets. 
Confocal microscopy revealed that tumours of mice treated with MEKi and 
Rosiglitazone, but not of control-treated mice, exhibited adipocytes expressing 
ZsGreen (Fig. 4a-c). We further observed that these adipocytes 
predominantly localized at the rim of the tumour next to the normal mammary 
fat pad. Confocal microscopy and 3D reconstruction analysis of the tumour 
rims on thick histological tumour sections (80µm) revealed that the invasive 
fronts observed in the control-treated tumours were completely impeded in 
tumours of Rosaglitazone/MEKi-treated mice (Fig. 4d,e). An appealing 
explanation for this finding is that tumour cells at the invasive front undergo an 
EMT or EMT-like changes allowing their transdifferentiation into adipocytes, 
and that this forced differentiation of invasive tumour cells keeps the tumour in 
a non-invasive, benign state. Delayed primary tumour growth in treated mice 
may thus be explained by their less aggressive growth pattern and by an 
inhibitory effect of the MEKi on proliferation. 
We then examined the effect of forced adipogenesis on metastasis 
formation in the two different treatment cohorts. For quantification of lung 
metastasis, metastatic nodules were classified in three groups: 
Macrometastases were defined as macroscopically identifiable metastases; 
medium-size metastases referred to microscopically detectable metastatic 
nodules, and micrometastases were individual cancer cells or cell clusters 
without clear metastatic outgrowth (Extended Data Fig. 4c). The number and 
size of metastases was found significantly reduced in the Rosiglitazone/MEKi-
treated mice as compared to control-treated mice (Fig. 4f).   
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Figure 4. In vivo adipogenesis of metastatic 4T1 murine breast cancer cells 
correlates with decreased invasion and metastatic colonization.  
ZsGreen-expressing 4T1 cells were injected into the mammary fat pad of female 
NMRI nu/nu mice. After initial primary tumour growth, mice were treated daily with 
vehicle (Control) or 2mg/kg MEKi PD98059 and 16mg/kg Rosiglitazone (Treated). 
After 17 days of treatment, mice were euthanized, and tumours and lungs were 
processed for histopathological analysis. n=6 mice per group.  
(a) 558/568 BODIPY (red) was used to visualize lipid droplets on 80µm thick frozen 
sections. Tumour cells are visualized by ZsGreen and nuclei by DAPI staining. 
Shown are representative images of tumour cells containing lipid droplets in tumours 
of treated mice (Treated) but not in tumours of control-treated mice (Control).   
(b,c) 7µm thick tumour sections were stained with BODIPY to identify adipocyte 
structures formed by differentiated ZsGreen-expressing 4T1 cells (green) using 
confocal microscopy. DAPI staining visualizes nuclei (b). 3-dimensional 
reconstructions of the confocal microscopy images using Imaris software (c). Scale 
bars, 10µm. 
(d,e) Representative confocal microscopy images of an invasive (Control) and a non-
invasive, smooth (Treated) tumour rim bordering to the mammary fat pad on 80µm 
thick sections stained with BODIPY (red). Tumour cells were visualized by ZsGreen 
and nuclei by DAPI staining (d). 3-dimensional reconstructions of (d) excluding 
BODIPY staining. Nuclei are visualized by DAPI staining. Scale bars, 100µm.  
(f) Quantification of lung metastasis in treated and control mice. The graph shows the 
number of metastases in each group (Control = green, Treated = purple) classified 
by size in macro, medium or micrometastases. Chi-square test, P-value <  2-16.  
(g,h) 80µm thick frozen sections of lungs were stained with BODIPY (red) to 
visualize adipocytes in the lungs using confocal microscopy (g) and 3-dimensional 
reconstruction (h). Tumour cells were visualized by ZsGreen and nuclei by DAPI 
staining. Scale bars, 10µm. 
 
 
We then assessed whether the treatment was able to induce 
adipogenesis in tumour cells invading the lungs. Thick histological lung 
sections (80µM) were stained with BODIPY to visualize lipid droplets. Here, 
BODIPY staining led to an extensive background staining of all cells. 
Nevertheless, individual ZsGreen and BODIPY double-positive tumour cells 
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were detected in the lungs of treated mice but not in control-treated mice (Fig. 
4g,h). Together, the data indicate that the forced adipogenesis of invasive 
tumour cells results in a reduction of primary tumour growth and invasion and 
of metastasis formation. 
 
3.3.5  Cancer Cell Plasticity Facilitates Adipogenesis 
The fact that we achieved a nearly 100% efficiency in converting murine 
breast cancer cells into adipocytes in vitro allowed a whole transcriptomic 
survey of changes in gene expression during a time course of mesenchymal 
breast cancer cells (MTΔECad) undergoing transdifferentiation into terminally 
differentiated adipocytes. Cells were harvested at six different time points 
during the adipogenesis time course and subjected to RNA sequencing (Fig. 
5a). Gene expression analysis documented a full transcriptomic conversion of 
malignant to benign differentiation. A clustered heat map of most variable 
genes in the time-course of differentiation demonstrated the extensive 
molecular changes cancer cells undergo when forced into adipogenesis  (Fig. 
5b). Notably, among the increased expression of adipocyte-specific genes, 
this analysis also identified the differentiated cells as white fat adipocytes 
expressing Resistin (Retn) and no UCP1, a marker for brown fat adipocytes 
(Fig. 5c).  
Analysis of cell cycle-related genes showed the down-regulation of 
proliferation-related genes alongside with the up-regulation of cell cycle 
arrest-related genes (Fig. 5d,e). This data further supports our findings that 
cancer cells undergoing adipogenesis exit the proliferative state and undergo 
cell-cycle arrest (see also Fig. 1d,e and Extended Data Fig. 2c).  
The gene expression data also provided insights into the possible 
mechanisms of how an EMT/MET interconversion may manifest cell plasticity 
and allow the transdifferentiation of breast cancer cells into adipocytes. For 
example, we noted that BMP2 had a crucial effect on the efficiency of 
adipogenesis in MTΔECad cells, yet not in Py2T-LT cells as shown by 
immunoblotting analysis and by Nile Red staining (Extended Data Fig. 5). 
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When inducing adipogenesis in Py2T-LT cells, TGFβ signalling had to be 
repressed to overcome its inhibitory effect on adipogenesis. However, the 
cells then slowly revert to their epithelial state by a MET. In contrast, 
MTΔECad cells lack E-cadherin and cannot revert back to the epithelial state, 
and we speculate that BMP2 initiates a MET-like process in MTΔECad cells in 
vitro resulting in the enhancement of cell plasticity. This notion is supported by 
the loss of mesenchymal marker gene expression and by the up-regulation of 
MET inducers, such as KLF4 (Tiwari et al., 2013), at the beginning of the 
transdifferentiation process (Fig. 5f). Notably, the transcription factors Zeb1 
and Zeb2, well-known inducers of EMT (Chaffer et al., 2013) as well as of 
adipogenesis (Gubelmann et al., 2014), are upregulated by BMP2 (Fig. 5f).  
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Figure 5. The transcriptome of cancer cell adipogenesis. 
(a) Schematic representation of the treatment protocol and timed microphotographs 
of MTΔECad cells undergoing forced adipogenesis in vitro. RNA was extracted for 
RNA sequencing at the days indicated.  
(b) Heat map of the top 25% most variably expressed genes during MTΔECad cell 
adipogenesis. 
(c) RNA sequencing analysis of selected adipogenesis-related genes at different 
time points of  MTΔECad cell adipogenesis. 
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(d) Heat map of cell cycle-related genes genes annotated in the GO database 
(GO:0007049) during MTΔECad cell adipogenesis. 
(e) RNA sequencing analysis of cell cycle-related genes at different time points of 
MTΔECad cell adipogenesis. 
(f) RNA sequencing analysis of selected EMT/MET-related genes at different time 
points of MTΔECad cell adipogenesis. 
 
3.4  Discussion  
Taken together, our data demonstrate that EMT in cancer correlates not only 
with malignant progression, but also with increased cell plasticity. This status 
of high cell plasticity in cancer cells can be exploited in vitro and in vivo to 
force differentiation into terminally differentiated and post-mitotic adipocytes 
with benign traits. Our proof-of-concept experiments in mouse models 
highlight the relevance of cancer plasticity not only as a means of cancer 
dissemination and survival but also as a possibility for novel therapeutic 
approaches. We note that the tested approaches have targeted specifically 
invasive, malignant cancer cells, thus efficiently repressing primary tumour 
invasion and metastasis, yet leaving highly proliferating epithelial tumour cells 
untouched. Therefore, further studies will be required to target tumour 
invasion and metastasis by the adipocyte transdifferentiation therapy reported 
here in combination with repressing tumour cell proliferation by cytostatic 
therapy. Since EMT has been demonstrated to increase resistance to 
chemotherapy and targeted therapy, we envision that the ablation of invasive 
mesenchymal cancer cells by transdifferentiation therapy will overcome 
therapy resistance and cancer relapse. Of course, improving and optimizing 
cancer cell transdifferentiation/adipogenesis with newer and more potent 
pharmacologicals will be the next step before assessing the clinical benefit of 
this approach.   
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3.6  Material and Methods 
Cell lines and cell culture 
3T3-L1 cell line was previously described (Green and Kehinde, 1975) and was a kind 
gift from Professor B Deplancke (EPFL, Lausanne). Py2T, MTflECad, MTΔECad 
were previously described (Fantozzi et al., 2014; Waldmeier et al., 2012). Cells were 
routinely tested for Mycoplasma contamination.  
All cells were cultured in Dulbecco’s modified eagle medium (DMEM; Sigma-
Aldrich) supplemented with fetal calf serum (FCS, 10 %; Sigma-Aldrich), 
glutamine (2 mM; Sigma-Aldrich), penicillin (100 U; Sigma-Aldrich) and 
streptomycin (0.2 mg/l; Sigma-Aldrich). All cell lines were grown at 37 °C, 5 % 
CO2, 95 % humidity. 
All in vitro experiments were independently repeated at least 3 times. No samples 
have been excluded from the analysis. 
 
Antibodies and fluorescent dyes 
C/EBPβ (E299, Abcam), PPARγ (81B8, Cell Signaling), Adiponectin (C45B10, 
Cell Signalling), ERK Diphospho (M8159, Sigma), ERK total (M7927, Sigma), 
Vinculin (S19, Santa Cruz), GLUT4 (ab65267, Abcam), PH3 (Upstate), 
Smad3 (9523, Cell Signaling), Smad3-Phospho (9520, Cell Signaling), α-SMA 
(F3777, Sigma), Nile Red (Sigma), BODIPY 558/568 (D3835, Thermo Fisher), 
BODIPY 493/503 (D3922, Thermo Fisher), Yap/Taz (sc-101199, Santa Cruz). 
 
In vitro adipogenesis  
Cells were seeded at density of 20,000 cells/cm2 and incubated overnight at 
37°C in 5% CO2. To induce differentiation of 3T3-L1, the growth medium was 
replaced with medium containing 5µg/ml insulin, 1µM Dexamethasone 
(dissolved in ethanol), 2µM Rosiglitazone (dissolved in DMSO) for 48 hours, 
then in medium containing 5µg/ml insulin for 48h, then in medium containing 
1µM Rosiglitazone. To induce differentiation in cancer cells, cells were 
seeded and incubated overnight, incubated with 200ng/ml human 
recombinant BMP2 (Sigma) for 3 days with 200ng/ml BMP2 and 2µM 
Rosiglitazone (Rosi) for 4 days, and with medium containing 2µM 
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Rosiglitazone for another 3 days. The addition of other growth factors or 
inhibitors is indicated in the figures, usually from day 0 to day 7 such as 
human recombinant TGFβ1 at 2ng/ml, the MEK inhibitor PD98059 at 40µM 
and the TGFβR1 inhibitor SB431542 at 10µM. Control cells were treated with 
medium containing DMSO.  
 
In vitro chondrogenesis  
Cells were seeded at a density of 60,000 cells/cm2 in normal growth medium 
(DMEM supplemented with glutamine, penicillin, streptomycin and 10% FBS) 
and incubated at 37°C in 5% CO2 over night. Medium was removed and cells 
were washed with serum free Opti-MEM media (to remove traces of serum). 
Differentiation medium: Opti-MEM serum free media (Gibco) containing ITS 
1% (BD), Dexamethasone 10uM  (Sigma Aldrich), Ascorbate 100 uM (Sigma 
Aldrich) and 10ng/ml human recombinant TGFβ1. One day later, medium was 
removed, and cells were washed. From day 2 to day 21, differentiation 
medium was replaced every 48 hours containing 10ng/ml human recombinant 
BMP2 and BMP4. For control cells normal culture medium was used. 
 
In vitro osteogenesis  
Cells were seeded at density of 20,000 cells/1cm2 in normal growth medium 
(DMEM supplemented with glutamine, penicillin, streptomycin and 10% FBS) 
and incubated at 37°C in 5% CO2 for 48 hours.  From day 2 until day 21 
differentiation medium was used: Supplemented DMEM containing 1mg/ml β-
Glycerophosphate (Calbiochem), 10-7M Dexamethasone and 100µM L-
Ascorbate, 1mM Sodium Pyruvate (Sigma) and 10 ng/ml human recombinant 
BMP4 was added each time. Control cells were incubated with culture 
medium. 
 
In vivo adipogenesis 
For primary tumour growth experiments, 0.5x106 GFP-expressing Py2T cells 
were injected into the mammary fat pad of 8-10 weeks old female RAG2-/-
;common γ receptor -/- (RSG) mice. After 2 weeks of initial tumour growth, 
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tumour volume was measured, and mice were divided into a control group 
(n=7), low treatment group (n=7) and high treatment group (n=7). 
Test on volume in the first day: Equal variances assumption does not hold, 
there for Wilcoxon test was used on each pair of groups, none of the three 
comparisons was significant: 
Comparison (tumour volume) Result 
Control vs low treatment 
W=24, P-value=0.731 
Control vs high treatment W=15, P-value=0.61 
Low treatment vs high treatment W=12, P-value=0.79 
 
Mice were treated daily with i.p injections of drugs or vehicle for two weeks. 
High dose group, PD98059 5mg/kg and Rosiglitazone 16mg/kg dissolved in 
vehicle; low dose group, PD98059 2mg/kg and Rosiglitazone 16mg/kg 
dissolved in vehicle; control group, vehicle alone (4%DMSO, 30% PEG300, 
5% Tween 80). Not included animals were euthanized during the experiment. 
Final group size: Control group (n=6), low treatment (n=7) and high treatment 
group (n=4). 
 
For tumour invasion and metastasis experiments, 8 weeks old female NMRI 
nu/nu mice were injected into the mammary fat pad with 0.5x106 ZsGreen-
expressing 4T1 cells. After 5 days of initial tumour growth, tumour volume was 
measured, and mice were divided into a control group (n=6) and a low dose 
group (n=6) treated as above. Test on volume in the first day: Equal variances 
assumption does not hold, there for Wilcoxon test was used. The groups’ 
means are not different W=14.5, P-value=0.624. Mice were treated daily with 
i.p. injections of drugs or vehicle for 17 days. 
 
Animals were sacrificed, tumour volumes and weights were measured, and 
tumours and lungs were embedded in paraffin for H&E staining and OCT for 
immunofluorescence staining and frozen for RNA isolation. 
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All studies involving mice have been approved by the Swiss Federal 
Veterinary Office (SFVO) and the Cantonal Veterinary Office of Basel Stadt 
(licenses 1878, 1907, and 1908). 
 
Lung metastasis quantification and statistical analysis 
The dataset consists of 12 mice, for each mouse the number of metastases 
was counted and classified by size types: “Macro”, “Medium” or “Micro” across 
9 slides per size type. The test aims to detect dependency between the 
metastases’ size type and group, using chi-square test on the frequency table 
below: 
 
Macro	 Medium	 Micro	 Total	
Control 134 383 134 651 
Treatment  9 110 148 267 
Total 143 493 282 N=918 
 
 
RNA isolation and RT-PCR 
Total RNA was prepared using TriReagent (Sigma-Aldrich) for cells or 
RNeasy mini kit (74104, Qiagen) for tissues. For RNA sequencing total RNA 
was isolated using miRNeasy mini kit (217004, Qiagen). RNA was reverse 
transcribed with M-MLV reverse transcriptase (Promega), and transcripts 
were quantified by PCR using SYBR-green PCR MasterMix (Invitrogen). 
Riboprotein L19 primers were used for normalization. PCR assays were 
performed in triplicate, and fold induction was calculated using the 
comparative Ct method (ΔΔ Ct). Primers used for quantitative RT-PCR are 
listed in table 1 
 
Immunofluorescence microscopy 
Cells were fixed with 4%PFA and permeabilized with 0.5% NP40. Cells were 
blocked with 3%BSA and incubated with primary antibody for 1.5h at room 
temperature or overnight at 4°C. After washing, cells were incubated with 
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secondary antibodies for 1h at room temperature, washed and incubated with 
DAPI for 10 minutes, and washed and mounted with fluorescent mounting 
medium (Dako). Samples were imaged with a confocal microscope (LSM 510 
Meta, Zeiss or Leica SP5) or with a fluorescence microscope (Leica 
DMI4000).   
 
GLUT4 translocation  
Before and after the full ten-days adipogenesis protocol, cells were incubated 
for 25 minutes with 100nM insulin or normal growth medium and subsequently 
analysed for the expression and localization of GLUT4 by 
immunofluorescence microscopy.  
 
EdU incorporation to detect proliferating cells 
Cells before and after a full ten-day adipogenesis protocol were incubated for 
24 hours with 1µM EdU (Invitrogen) or 72 hours with 0.1µM EdU. Cells were 
fixed with 4% PFA for 20 minutes, washed with PBS, permeabilized with 0.5% 
NP40 and washed with PBS-T (PBS + 0,01% TX-100). ClickIT reaction was 
performed according to the manufacturer’s protocol (BaseClick), cells were 
washed with PBS-T and used for immunostaining.  
 
BODIPY staining on frozen sections 
Cryosections (7µM or 80µM) were rehydrated in PBS and incubated with 
BODIPY in the dark at room temperature for 30 minutes. Cells were washed 
and incubated with DAPI for 10 minutes, then washed and mounted with 
fluorescent mounting medium (Dako). 
 
Immunoblotting 
Cells were lysed in boiling lysis buffer (0.29M Tris-HCl PH6.8, 4.7% SDS, 
23% glycerol). Protein concentration was determined using the BCA assay kit 
(Pierce). Equal amounts of protein were diluted in SDS-PAGE loading buffer 
(10% glycerol, 2% SDS, 65 mM Tris, 1 mg/100 ml bromophenol blue, 1% β-
mercaptoethanol) and resolved by SDS-PAGE. Proteins were transferred to 
nitrocellulose, 0.45µM pore size membranes by wet transfer, blocked with 5% 
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skim milk powder in TBS/0.05% Tween 20 and incubated with the antibodies 
indicated. HRP-conjugated secondary antibodies were detected by 
chemiluminescence using a Fusion Fx7 chemiluminescence reader (Vilber 
Lourmat, France). 
 
RNA sequencing analysis 
Total RNA was isolated from cells of 2 independent experiments using the 
RNeasy Mini Kit (Qiagen) according to the manufacturer’s instruction. RNA 
quality control was performed with a fragment analyser using the standard or 
high sensitivity RNA analysis kit (DNF-471-0500 or DNF-472-0500) from 
Labgene and RNA concentration was measured by using the Quanti-iTTM 
RiboGreen RNA assay kit (Life Technologies/Thermo Fisher Scientific). 200 
ng of RNA was utilized for library preparation with the TruSeq Stranded Total 
RNA LT Sample Prep Kit (Illumina). Poly-A+ RNA was sequenced by HiSeq 
SBS kit v4 (Illumina) on an Illumina HiSeq 2500 using protocols defined by the 
manufacturer. 
Obtained single-end RNA-seq reads (63-mers) were mapped to the mouse 
genome assembly, version mm10, with RNA-STAR (Dobin et al., 2013), with 
default parameters except for allowing only unique hits to genome 
(outFilterMultimapNmax=1) and filtering reads without evidence in spliced 
junction table (outFilterType="BySJout"). Using RefSeq mRNA coordinates 
from UCSC (genome.ucsc.edu, downloaded in December 2015) and the 
qCount function from QuasR package (version 3.12.1), we quantified gene 
expression as the number of reads that started within any annotated exon of a 
gene. The differentially expressed genes were identified using the edgeR 
package (version 1.10.1). Genes with FDR smaller than 0.05 and minimum 
log2 fold change of +/-1 were used for downstream analysis. 
 
Statistical analysis 
Statistical analysis and graphs were generated using the R software and 
GraphPad Prism software. Statistical analysis was preformed as indicated in 
the figure legends.  
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Table 1. RT-PCR primers 
Gene 
(mouse) 
Primers 
Pparγ2  GCTGTGAAGTTCAATGCACTGG 
 
GCAGTAGCTGCACGTGCTCTG 
Adipoq  TGTTCCTCTTAATCCTGCCCA 
 
CCAACCTGCACAAGTTCCCTT 
FABP4  GATGCCTTTGTGGGAACCT 
 
CTGTCGTCTGCGGTGATTT 
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3.7 Extended Data Figures 
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Extended Data Figure 1. Adipogenesis can be induced in EMT-derived cancer 
cells but not in their epithelial ancestors. 
(a) Epithelial MTflEcad cells (upper panels) and mesenchymal MTΔECad cells (lower 
panels) were treated to induce adipogenesis. The early adipogenesis regulator 
C/EBPβ and the actin cytoskeleton (Phalloidin) were visualized by 
immunofluorescence stainings. Scale bars, 100µm.  
(b) Adipogenesis was induced in MTΔECad cells for 10 days, and mRNA levels of 
PPARγ2 (early adipogenesis) and Adipoq (mature adipocytes) were quantified by 
quantitative RT-PCR at the time points indicated. The graph shows means ± 
standard deviation (s.d.). 
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Extended Data Figure 2. Cancer cells undergoing post-mitotic differentiation 
into adipocytes lose their invasive, mesenchymal traits.  
(a) Immunostaining of adipogenesis-induced MTΔECad cells (Treated) or control-
treated cells (Control) for the mesenchymal marker alpha smooth muscle actin (α-
SMA, green) and for the adipocyte marker Adipoq (red). Scale bars, 100µm. 
(b) Immunostaining of adipogenesis-induced or control-treated Py2T-LT cells for 
Adipoq (green) and the actin cytoskeleton (Phalloidin, red). The cells were in addition 
treated with TGFβR inhibitor (TGFβRi; SB431542) as indicated. Scale bars, 100µm. 
(c) MTΔECad and in 3T3-L1 were treated to undergo adipogenesis for 10 days 
(Treated) or treated with solvent (Control). MTΔECad cells were in addition treated 
with TGFβ or TGFβR1 inhibitor (TGFβR1i; SB431542) as indicated. Levels of 
proliferation-related phospho-histone 3 (PH3) and CyclinD1 as well as of the 
adipogenesis regulator PPARγ were determined by immunoblotting analysis.  
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Extended Data Figure 3. GFP-labelled Py2T breast cancer cells undergo 
differentiation into adipocytes in vivo. 
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GFP-expressing Py2T cells were injected into the mammary fat pad of female RAG2 
-/-;common γ receptor -/- (RSG) mice. After initial tumour growth, mice were treated 
daily with vehicle (Control) or 2mg/kg MEK inhibitor (MEKi, PD98059) and 16mg/kg 
Rosiglitazone (Low treatment) or 5mg/kg MEKi (PD98059) and 16mg/kg 
Rosiglitazone (High treatment). After 14 days of treatment mice were sacrificed and 
tumours sectioned and stained.  
(a) mRNA levels of Adipoq and FABP4 in tumours of control, low treatment and high 
treatment groups were detected by quantitative RT-PCR. The graph shows means ± 
standard deviation (s.d.). Student’s t-test; P-value: * < 0.05; NS, not significant.  
(b) Tumour weights in mice of the control, low treatment and high treatment groups. 
The graph shows means ± SEM. Student’s t-test; NS, not significant. 
(c) Representative images of adipocytes inside tumours in both control and treated 
mice. Lipid droplets were visualized with BODIPY (red) and fluorescence 
microscopy; Scale bars, 100µm.  
(d) Co-localization of GFP (labelled Py2T cells) and BODIPY was visualized by 
confocal microscopy in control and treated tumours. Scale bars, 10µm. 
(e) The adipocyte cellular structure of (d) was visualized by 3-dimensional 
reconstruction using Imaris software. Scale bars, 10µm. 
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Extended Data Figure 4 In vivo adipogenesis of metastatic 4T1 murine breast 
cancer cells correlates with decreased invasion and metastatic colonization. 
Further analysis of the experiment described in Figure 4.  
(a) Tumour weights of control or treated animals were determined after euthanasia. 
The graph shows means ± SEM. Student’s t-test; P-value < 0.05.  
(b) Tumours size was measured at least once per week over time and after 
euthanasia (day 17). A random intercept regression model with an interaction term 
between the group and day of measurement was fitted after performing box-cox 
transformation on the volume with λ = 0.303. Graph shows transformed volume for 
fitted values as well as the 95% confidence interval (CI) in each group, control 
(orange) and treatment (blue). Significant interaction term between the group factor 
and number of days (P-value: * = 0.0011)  
(c) Lungs were sectioned and stained by hematoxilin and eosin (H&E). 
Representative images of macroscopically detectable lung metastases 
(Macrometastasis), medium-sized metastases (Medium), and microscopically visible, 
infiltrating tumour cells (Micrometastasis) are shown. 
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Extended Data Figure 5. Role of BMP2 in adipogenesis of EMT-derived cancer 
cells. 
(a,b) Mesenchymal Py2T-LT cells (a) and MTΔECad cells (b) were treated as 
indicated for 7 days and the expression of the adipogenesis regulator PPARγ was 
analysed by immunoblotting. Detection of vinculin was used as loading control. 
(c) Py2T-LT cells were treated as indicated for 10 days and then stained with Nile 
Red (red) to visualize lipid droplets. (TGFβR1i, SB431542; MEKi, PD98059; Rosi, 
Rosiglitazone). Scale bars, 100µm. 
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3.8 Supplementary Data Figures 
 
 
Supplementary Figure 1: Yap/Taz translocation during adipogenesis correlates 
with decreased proliferation 
a, During adipogenesis induction in MTΔECad cells, Yap and Taz (red) localization 
and Cebpα (green) expression were visualized by immunofluorescence staining. b, 
The same cells were incubated with EdU for 24 hours to detect proliferating cells. 
Representative images show EdU (green) and DAPI (blue) stainings. Scale bars: 
100µm 
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Supplementary Figure 2: Adipocyte- derived breast cancer cells revert neither 
to mesenchymal nor to epithelial cells 
a, b, MTΔECad cells were treated to induce adipogenesis.  Cells were incubated for 
further 7 days with normal culture medium and representative images were taken (a). 
Cells were trypsinized and replated in a collagen I pre-coated- flask. The flask was 
filled completely with culture medium and placed up side down to allow adipocytes to 
adhere to the flask’s bottom. After 7 days of incubation medium was removed and 
cells stained with Nile Red (Red) to visualize lipid droplets (b). Scale bars: 100µm. 
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4 Outlook and Future Plans 
The introduction section defines cellular plasticity as a quality of the cell that 
determines the cell’s capacity to adapt to environmental cues. EMT and MET 
represent a paradigm to plasticity, they are evident in various types of cells 
and have been demonstrated essential for many biological processes. I argue 
that EMT and MET can be viewed as processes contemporaneous to the cell 
differentiation state and are therefore activated during cellular adaptation and 
modification processes, including cellular reprogramming to iPSC. Given the 
enhanced plasticity acquired by EMT/MET in different cell types, it will be 
necessary to reveal the molecular essence of these processes. Distinguishing 
cell plasticity events from cell identity-related processes in EMT could 
substantiate our understanding of cell plasticity.   
In order to identify the molecular plasticity mechanisms underlying 
EMT/MET, we have recently initiated a study comparing the transcriptomic 
changes during EMT/MET and cell reprogramming in iPSC. We ask whether a 
plasticity signature can be revealed when finding the similarities between 
these processes. Such a signature can potentially be composite of specific 
gene expression or favourable reciprocal connection between different 
recognized cellular mechanisms. We speculate that understanding the 
molecular mechanisms underlying cell plasticity will enable a better 
understanding of cell fate decisions and cancer plasticity. 
It is likely that the EMT/MET processes observed in vivo are only 
partial and/or transient. To evaluate the role of EMT/MET in cancer 
progression and validate the potential of adipogenesis therapy, lineage-
tracing studies are required.  The monitoring of cancer cells that have initiated 
an EMT program, even if not to its full extent, will allow an assessment 
whether adipogenesis utilizes the acquired plasticity in all cells. Zeb1 has 
been suggested as a crucial EMT transcription factor associated with plasticity 
and important also for adipogenesis. Therefore, a possible approach is to 
generate 4T1 breast cancer cells carrying a Zeb1 promoter-reporter and 
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transplant them into mice for adipogenesis treatment. This could be used to 
detect tumour cells that had initiated an EMT program. Correlating Zeb1 
expression with the expression of adipogenesis genes may provide additional 
insights into the molecular mechanisms underlying cell plasticity and into the 
efficiency of differentiation therapy to target cancer cell plasticity.   
Cancer cell dormancy seems to facilitate cancer cell survival and is an 
underlying mechanism for cancer latency. Adipogenesis, on the other hand, 
requires cell cycle arrest to allow terminal differentiation, and adipocytes 
represent postmitotic cells. It is therefore possible that adipogenesis therapy 
can target and force differentiation also of dormant cancer cells. This may 
allow a therapeutic approach to inhibit breast cancer recurrence. However, 
further studies on the effect of adipogenesis treatment on dormant bone 
marrow-infiltrating tumour cells will be required.  
As described in the discussion section of this work, adipogenesis 
therapy is aimed to target specifically cancer cell plasticity. Non-invasive 
tumour cells and re-differentiated tumour cells at the metastatic organ will 
require classical treatment with targeted therapies or chemotherapy. It is 
intriguing to test the benefit of combining these approaches in mouse models 
of breast cancer. Notably, it is plausible that adipogenesis will inhibit the 
development of drug resistant cells. 
Finally, MEK inhibition, though clinically used for cancer treatment, 
exhibits high toxicity. Delineating the role of BMP2 in breast cancer cell 
adipogenesis in vitro and the transcriptomic analysis of this process will be 
instrumental for identifying new specific targets to induce adipogenesis. To 
reveal the role of BMP2 derived from MTΔEcad and Py2T-LT cells treated for 
seven days with the adipogenesis differentiation protocol with and without 
BMP2. The analysis of these data will provide further insights into the 
pathways that can induce adipogenesis in malignant cancer cells.   
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